{"id":12718,"date":"2026-02-17T18:46:40","date_gmt":"2026-02-17T18:46:40","guid":{"rendered":"https:\/\/csiag.eu\/?p=12718"},"modified":"2026-02-17T20:56:03","modified_gmt":"2026-02-17T20:56:03","slug":"mogad-mog-onemocneni-spojene-s-protilatkami","status":"publish","type":"post","link":"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/","title":{"rendered":"MOGAD - onemocn\u011bn\u00ed spojen\u00e9 s protil\u00e1tkami MOG"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_87_1 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Obsah<\/p>\n<span class=\"ez-toc-title-toggle\"><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_ist_MOGAD\" >Co je MOGAD?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_geht_bei_MOGAD_schief\" >Co se d\u011bje v MOGADu?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wo_im_Korper_passiert_das\" >Kde v t\u011ble k tomu doch\u00e1z\u00ed?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_verlauft_die_Erkrankung\" >Jak nemoc postupuje?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_haufig_ist_MOGAD\" >Jak \u010dast\u00fd je MOGAD?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Was_lost_MOGAD_aus\" >Co je spou\u0161t\u011b\u010dem MOGAD?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wie_wird_MOGAD_behandelt\" >Jak se l\u00e9\u010d\u00ed MOGAD?<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wissenschaftliche_Einleitung_und_Definition\" >V\u011bdeck\u00fd \u00favod a definice<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Abgrenzung_von_MOGAD_NMOSD_und_MS\" >Rozli\u0161en\u00ed mezi MOGAD, NMOSD a MS<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOG-Protein_%E2%80%93_Struktur_und_physiologische_Funktion\" >Protein MOG - struktura a fyziologick\u00e1 funkce<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Strukturdomanen\" >Strukturn\u00ed dom\u00e9ny<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Physiologische_Funktionen\" >Fyziologick\u00e9 funkce<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Pathogenese_und_Immunpathologie\" >Patogeneze a imunopatologie<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Trigger_und_initiale_Aktivierung\" >Spou\u0161t\u011bn\u00ed a po\u010d\u00e1te\u010dn\u00ed aktivace<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#T-Zell-vermittelte_Pathogenese\" >Patogeneze zprost\u0159edkovan\u00e1 T-bu\u0148kami<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_1_%E2%80%93_Periphere_Aktivierung\" >F\u00e1ze 1 - perifern\u00ed aktivace<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_2_%E2%80%93_BHS-Penetration\" >F\u00e1ze 2 - pronik\u00e1n\u00ed BHS<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_3_%E2%80%93_Perivaskulare_Reaktivierung\" >F\u00e1ze 3 - Perivaskul\u00e1rn\u00ed reaktivace<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#B-Zell-_und_Antikorper-vermittelte_Pathogenese\" >Patogeneze zprost\u0159edkovan\u00e1 B-bu\u0148kami a protil\u00e1tkami<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Molekulare_Signalwege_und_Effektormechanismen\" >Molekul\u00e1rn\u00ed sign\u00e1ln\u00ed dr\u00e1hy a efektorov\u00e9 mechanismy<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_1_%E2%80%93_Klassischer_Komplementweg_CDC\" >Sign\u00e1ln\u00ed dr\u00e1ha 1 - klasick\u00e1 komplementov\u00e1 dr\u00e1ha (CDC)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_2_%E2%80%93_Fc%CE%B3-Rezeptor-Weg_FcR-vermittelt\" >Sign\u00e1ln\u00ed dr\u00e1ha 2 - dr\u00e1ha receptoru Fc\u03b3 (zprost\u0159edkovan\u00e1 FcR)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_3_%E2%80%93_IL-6JAK-STAT3-Weg\" >Sign\u00e1ln\u00ed dr\u00e1ha 3 - dr\u00e1ha IL-6\/JAK-STAT3<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_4_%E2%80%93_MAPK-_und_AKT-Signalwege_B-Zellen\" >Sign\u00e1ln\u00ed dr\u00e1ha 4 - sign\u00e1ln\u00ed dr\u00e1hy MAPK a AKT (B bu\u0148ky)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalweg_5_%E2%80%93_Th17-Zytokin-Netzwerk_im_ZNS\" >Sign\u00e1ln\u00ed dr\u00e1ha 5 - s\u00ed\u0165 cytokin\u016f Th17 v CNS<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Signalwege_%E2%80%93_Ubersicht\" >Sign\u00e1ln\u00ed dr\u00e1hy - p\u0159ehled<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Relevante_Rezeptoren_und_Zielmolekule\" >Relevantn\u00ed receptory a c\u00edlov\u00e9 molekuly<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOG_selbst_als_Zielstruktur_kein_klassischer_Rezeptor\" >samotn\u00fd MOG jako c\u00edlov\u00e1 struktura (nikoli klasick\u00fd receptor)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Fc%CE%B3-Rezeptoren_Fc%CE%B3R\" >Receptory Fc\u03b3 (Fc\u03b3R)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Neonataler_Fc-Rezeptor_FcRn\" >Neonat\u00e1ln\u00ed Fc receptor (FcRn)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#IL-6-Rezeptor_IL-6R%CE%B1_gp130\" >Receptor IL-6 (IL-6R\u03b1 \/ gp130)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#T-Zell-Rezeptor_TCR_und_Kostimulationsmolekule\" >T-bun\u011b\u010dn\u00fd receptor (TCR) a kostimula\u010dn\u00ed molekuly<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Komplementrezeptoren\" >Receptory komplementu<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Histopathologie_und_ZNS-Lasionsmuster\" >Histopatologie a obraz l\u00e9z\u00ed CNS<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Klinische_Manifestationen_und_Phanotypen\" >Klinick\u00e9 projevy a fenotypy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Diagnostik\" >Diagnostika<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-37\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Therapeutische_Strategien\" >Terapeutick\u00e9 strategie<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-38\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Akuttherapie_Schubbehandlung\" >Akutn\u00ed l\u00e9\u010dba (l\u00e9\u010dba relapsu)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-39\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Prophylaktische_Langzeittherapie\" >Profylaktick\u00e1 dlouhodob\u00e1 l\u00e9\u010dba<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-40\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Klinische_Studien_%E2%80%93_2024%E2%80%932026\" >Klinick\u00e9 studie - 2024-2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-41\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Neue_und_zukunftige_Therapiekonzepte\" >Nov\u00e9 a budouc\u00ed koncepty terapie<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-42\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#BTK-Inhibitoren_Bruton-Tyrosin-Kinase\" >Inhibitory BTK (Brutonova tyrozinkin\u00e1za)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-43\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Toleranzinduktion_MOG-Tolerisierung\" >Navozen\u00ed tolerance (tolerance MOG)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-44\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Komplementinhibitoren\" >Inhibitory komplementu<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-45\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Anti-Neonatal-Fc-Rezeptor-Strategien\" >Strategie proti neonat\u00e1ln\u00edmu Fc receptoru<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-46\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Autologe_hamatopoetische_Stammzelltransplantation_aHSCT\" >Autologn\u00ed transplantace krvetvorn\u00fdch bun\u011bk (aHSCT)<\/a><\/li><\/ul><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-47\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Biomarker_und_Verlaufsmonitoring\" >Biomarkery a n\u00e1sledn\u00e9 sledov\u00e1n\u00ed<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-48\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Prognose_und_Besonderheiten\" >P\u0159edpov\u011b\u010f a speci\u00e1ln\u00ed funkce<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-49\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Zusammenfassung_und_Ausblick\" >Shrnut\u00ed a v\u00fdhled<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-50\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Atherischer_Ole_%E2%80%93_Wirkstoffe_nach_Signalwegen_geordnet\" >Esenci\u00e1ln\u00ed oleje - \u00fa\u010dinn\u00e9 l\u00e1tky se\u0159azen\u00e9 podle sign\u00e1ln\u00edch drah<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-51\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Weihrauch_Boswellia_serrata_%E2%80%93_AKBA_und_Incensolacetat\" >Kadidlo (Boswellia serrata) - AKBA a incensol acet\u00e1t<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-52\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Therapeutisch_relevante_AKBA-Zieldosen\" >Terapeuticky relevantn\u00ed c\u00edlov\u00e9 d\u00e1vky AKBA<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-53\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Umrechnung_auf_375_mg_AKBA_jeKapsel\" >P\u0159evod na 37,5 mg AKBA na kapsli<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-54\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wichtige_Einnahmehinweise\" >D\u016fle\u017eit\u00e9 pokyny pro p\u0159\u00edjem<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-55\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Schwarzer_Pfeffer_oral\" >\u010cern\u00fd pep\u0159 (peror\u00e1ln\u011b)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-56\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Schwarzer_Pfeffer_Inhalation\" >\u010cern\u00fd pep\u0159 (inhalace)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-57\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Copaiba-Ol_oral_%E2%80%93_NUR_doTERRA\" >Olej z kopaiby (peror\u00e1ln\u00ed) - POUZE doTERRA<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-58\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOGAD-spezifische_Dosierungstabelle_doTERRA_Copaiba_525_BCP\" >D\u00e1vkovac\u00ed tabulka specifick\u00e1 pro MOGAD (doTERRA Copaiba 52.5 % BCP)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-59\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#MOGAD-Phasen-adaptierte_Dosierung\" >F\u00e1zov\u011b p\u0159izp\u016fsoben\u00e9 d\u00e1vkov\u00e1n\u00ed MOGAD<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-60\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_1_Akuter_Schub_erste_2%E2%80%934_Wochen\" >F\u00e1ze 1: Akutn\u00ed vzplanut\u00ed (prvn\u00ed 2-4 t\u00fddny)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-61\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_2_Schubremission_Erhaltung_langfristig\" >F\u00e1ze 2: remise relapsu \/ udr\u017eov\u00e1n\u00ed (dlouhodob\u00e9)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-62\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Phase_3_Monophasischer_Verlauf_Titer_fallend\" >F\u00e1ze 3: Monof\u00e1zick\u00fd pr\u016fb\u011bh (klesaj\u00edc\u00ed titr)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-63\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Quellen\" >Zdroje<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-64\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Copaiba-Ol_Inhalation\" >Olej z kopaiby (inhalace)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-65\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Zieldosen_und_benotigte_Tropfenzahl\" >C\u00edlov\u00e9 d\u00e1vky a po\u017eadovan\u00fd po\u010det kapek<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-66\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Synergistische_MOGAD-Strategie_Multi-Target\" >Synergick\u00e1 strategie MOGAD (v\u00edce c\u00edl\u016f)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-67\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wichtige_MOGAD-spezifische_Hinweise\" >D\u016fle\u017eit\u00e9 informace specifick\u00e9 pro MOGAD<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-68\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#%CE%B1-Asaron_Kalmus-Ol_Acorus_calamus_%E2%80%93_direkt_oligodendrozytenprotektiv\" >\u03b1-Asaron (kalamitn\u00ed olej, Acorus calamus) - p\u0159\u00edmo oligodendrocyt\u00e1rn\u011b ochrann\u00fd<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-69\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Geraniumol_Pelargonium_graveolens_%E2%80%93_Neuroinflammation_und_NO\" >Pelargoniov\u00fd olej (Pelargonium graveolens) - neuroz\u00e1n\u011bt a NO<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-70\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Teebaum-Ol_Melaleuca_alternifolia_%E2%80%93_Mikroglia-Modulation\" >Tea tree oil (Melaleuca alternifolia) - modulace mikroglie<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-71\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Wirkstoffubersicht_nach_MOGAD-Signalwegen\" >P\u0159ehled \u00fa\u010dinn\u00fdch l\u00e1tek podle sign\u00e1ln\u00edch drah MOGAD<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-72\" href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/#Quellen_und_weiterfuhrende_Literatur\" >Zdroje a dal\u0161\u00ed literatura<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Doba \u010dten\u00ed<\/span> <span class=\"rt-time\"> 17<\/span> <span class=\"rt-label rt-postfix\">minuty<\/span><\/span>\n<p class=\"wp-block-paragraph\"><em>Onemocn\u011bn\u00ed spojen\u00e9 s protil\u00e1tkami proti myelinov\u00fdm oligodendrocyt\u016fm<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_ist_MOGAD\"><\/span>Co je MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Elektrick\u00e9 kabely zn\u00e1 ka\u017ed\u00fd: Jsou opat\u0159eny izolac\u00ed, kter\u00e1 odd\u011bluje jednotliv\u00e9 vodi\u010de ve svazku kabel\u016f od sebe navz\u00e1jem, aby se sign\u00e1ly v nich vz\u00e1jemn\u011b neru\u0161ily a dostaly se neru\u0161en\u011b z bodu A do bodu B.<br>M\u00edcha obsahuje celou \u0159adu takov\u00fdch kabelov\u00fdch svazk\u016f. Ty vedou nervov\u00e9 sign\u00e1ly z mozku do r\u016fzn\u00fdch org\u00e1n\u016f, sval\u016f, tk\u00e1n\u00ed atd. v t\u011ble. Zat\u00edmco izolace kabelu je vyrobena z plastu, textilu nebo speci\u00e1ln\u00edch materi\u00e1l\u016f, izola\u010dn\u00ed vrstva m\u00edchy je vyrobena ze speci\u00e1ln\u00edho materi\u00e1lu. <strong>Myelinov\u00e1 vrstva<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_geht_bei_MOGAD_schief\"><\/span>Co se d\u011bje v MOGADu?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">V p\u0159\u00edpad\u011b MOGAD se vlastn\u00ed imunitn\u00ed syst\u00e9m dopou\u0161t\u00ed z\u00e1va\u017en\u00e9 chyby: myln\u011b produkuje <strong>Protil\u00e1tky proti specifick\u00e9mu proteinu na vn\u011bj\u0161\u00ed stran\u011b t\u00e9to izola\u010dn\u00ed vrstvy.<\/strong>, tzv. <strong>MOG<\/strong>-protein. Protil\u00e1tky jsou vlastn\u011b str\u00e1\u017eci t\u011bla, kte\u0159\u00ed rozpozn\u00e1vaj\u00ed, ozna\u010duj\u00ed a ni\u010d\u00ed patogeny, jako jsou viry a bakterie. V p\u0159\u00edpad\u011b MOGAD jsou v\u0161ak omylem nam\u00ed\u0159eny proti vlastn\u00ed zdrav\u00e9 tk\u00e1ni, izolaci vlastn\u00edch nervov\u00fdch vl\u00e1ken.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">V porovn\u00e1n\u00ed s kabelem je to jako po\u0161kr\u00e1b\u00e1n\u00ed, od\u0159en\u00ed nebo koroze izolace, co\u017e zp\u016fsob\u00ed jej\u00ed perforaci a elektrick\u00e9 sign\u00e1ly ji\u017e nedos\u00e1hnou sv\u00e9ho c\u00edle \u010dist\u011b nebo dokonce v\u016fbec.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wo_im_Korper_passiert_das\"><\/span>Kde v t\u011ble k tomu doch\u00e1z\u00ed?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD se t\u00fdk\u00e1 v\u00fdhradn\u011b <strong>Centr\u00e1ln\u00ed nervov\u00fd syst\u00e9m<\/strong>, tj. mozek, m\u00edchu a o\u010dn\u00ed nervy. V z\u00e1vislosti na tom, kter\u00e1 oblast je posti\u017eena, vznikaj\u00ed r\u016fzn\u00e9 p\u0159\u00edznaky:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Zrakov\u00fd nerv<\/strong> - N\u00e1hl\u00e1 ztr\u00e1ta zraku, rozmazan\u00e9 vid\u011bn\u00ed, bolest o\u010d\u00ed (\u010dasto pouze jednoho oka, n\u011bkdy obou o\u010d\u00ed sou\u010dasn\u011b - to je u MOGAD \u010dast\u011bj\u0161\u00ed ne\u017e u jin\u00fdch podobn\u00fdch onemocn\u011bn\u00ed).<\/li>\n\n\n\n<li><strong>M\u00edcha<\/strong> - P\u0159\u00edznaky ochrnut\u00ed, necitlivost, probl\u00e9my s mo\u010den\u00edm<\/li>\n\n\n\n<li><strong>Mozek :<\/strong> Zmatenost, epileptick\u00e9 z\u00e1chvaty, poruchy koordinace.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_verlauft_die_Erkrankung\"><\/span>Jak nemoc postupuje?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD obvykle prob\u00edh\u00e1 v <strong>Tla\u010d\u00ed na<\/strong>. Existuj\u00ed f\u00e1ze, kdy je z\u00e1n\u011bt aktivn\u00ed a objevuj\u00ed se p\u0159\u00edznaky, kter\u00e9 se st\u0159\u00eddaj\u00ed s klidn\u011bj\u0161\u00edmi f\u00e1zemi.<br>Po prod\u011blan\u00e9 epizod\u011b se mnoz\u00ed pacienti p\u0159ekvapiv\u011b dob\u0159e zotavuj\u00ed, l\u00e9pe ne\u017e nap\u0159\u00edklad u RS. Je to proto, \u017ee samotn\u00e1 nervov\u00e1 vl\u00e1kna jsou \u010dasto m\u00e9n\u011b pravd\u011bpodobn\u011b trvale po\u0161kozena ne\u017e izola\u010dn\u00ed vrstva, kter\u00e1 se m\u016f\u017ee \u010d\u00e1ste\u010dn\u011b regenerovat.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">P\u0159ibli\u017en\u011b polovina posti\u017een\u00fdch za\u017eije pouze jedno vzplanut\u00ed za \u017eivot. Druh\u00e1 polovina m\u00e1 opakovan\u00e9 p\u0159\u00edhody, kter\u00e9 mohou v\u00e9st k trval\u00e9mu posti\u017een\u00ed, pokud se nel\u00e9\u010d\u00ed.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_haufig_ist_MOGAD\"><\/span>Jak \u010dast\u00fd je MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD je vz\u00e1cn\u00fd, pouze odhadovan\u00fd <strong>1-2 ze 100 000 lid\u00ed<\/strong> onemocn\u00ed. Na rozd\u00edl od mnoha jin\u00fdch autoimunitn\u00edch onemocn\u011bn\u00ed nervov\u00e9ho syst\u00e9mu postihuje \u017eeny a mu\u017ee zhruba ve stejn\u00e9m po\u010dtu. Nemoc\u00ed mohou onemocn\u011bt i d\u011bti, u kter\u00fdch se \u010dasto projevuje rozs\u00e1hl\u00fdm z\u00e1n\u011btem mozku se zmatenost\u00ed a hore\u010dkou.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Was_lost_MOGAD_aus\"><\/span>Co je spou\u0161t\u011b\u010dem MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Po prvn\u00ed epizod\u011b \u010dasto n\u00e1sleduje <strong>Infekce<\/strong> dop\u0159edu. T\u011blo bojuje proti patogenu a myln\u011b si plete vlastn\u00ed struktury s nep\u0159\u00edtelem. Imunitn\u00ed syst\u00e9m se nau\u010d\u00ed \u00fato\u010dit tak\u0159\u00edkaj\u00edc na nespr\u00e1vn\u00fd c\u00edl a nikdy se nezastav\u00ed. P\u0159esn\u00e1 p\u0159\u00ed\u010dina nen\u00ed dosud zcela objasn\u011bna. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wie_wird_MOGAD_behandelt\"><\/span>Jak se l\u00e9\u010d\u00ed MOGAD?<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">V sou\u010dasn\u00e9 dob\u011b neexistuje \u017e\u00e1dn\u00fd speci\u00e1ln\u011b schv\u00e1len\u00fd l\u00e9k na MOGAD. Jeden <strong>akutn\u00ed z\u00e1chvat<\/strong> se l\u00e9\u010d\u00ed vysok\u00fdmi d\u00e1vkami <strong>Kortizonov\u00e9 infuze<\/strong>, kter\u00e9 rychle tlum\u00ed z\u00e1n\u011bt. Pokud to nesta\u010d\u00ed <strong>Myt\u00ed krve<\/strong> (<em>Plazmafer\u00e9za<\/em>) lze \u0161kodlivou protil\u00e1tku odstranit p\u0159\u00edmo z krve.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Na <strong>Prevence dal\u0161\u00edch relaps\u016f<\/strong> Ke zklidn\u011bn\u00ed imunitn\u00edho syst\u00e9mu se pou\u017e\u00edvaj\u00ed r\u016fzn\u00e9 l\u00e9ky, nap\u0159\u00edklad l\u00e1tky, kter\u00e9 sni\u017euj\u00ed po\u010det bun\u011bk produkuj\u00edc\u00edch protil\u00e1tky. V sou\u010dasn\u00e9 dob\u011b se v klinick\u00fdch studi\u00edch testuje n\u011bkolik nov\u00fdch, c\u00edlen\u011bj\u0161\u00edch l\u00e9k\u016f, kter\u00e9 by mohly b\u00fdt v p\u0159\u00ed\u0161t\u00edch letech schv\u00e1leny.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wissenschaftliche_Einleitung_und_Definition\"><\/span>V\u011bdeck\u00fd \u00favod a definice<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Na str\u00e1nk\u00e1ch <strong>Onemocn\u011bn\u00ed spojen\u00e9 s protil\u00e1tkami MOG (MOGAD)<\/strong> Angli\u010dtina: <em>Onemocn\u011bn\u00ed spojen\u00e9 s protil\u00e1tkami proti myelinov\u00fdm oligodendrocyt\u016fm<\/em> je vz\u00e1cn\u00e9 z\u00e1n\u011btliv\u00e9 autoimunitn\u00ed onemocn\u011bn\u00ed centr\u00e1ln\u00edho nervov\u00e9ho syst\u00e9mu (CNS), kter\u00e9 je od roku 2018 uzn\u00e1v\u00e1no jako samostatn\u00e1 jednotka s vlastn\u00edmi diagnostick\u00fdmi krit\u00e9rii. D\u0159\u00edve bylo pova\u017eov\u00e1no za variantu roztrou\u0161en\u00e9 skler\u00f3zy (RS) nebo za poruchu spektra neuromyelitis optica (NMOSD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Z\u00e1kladn\u00edm prvkem onemocn\u011bn\u00ed je patologick\u00e1 tvorba autoprotil\u00e1tek (IgG) proti bu\u0148k\u00e1m. <strong>Myelinov\u00fd oligodendrocyt\u00e1rn\u00ed glykoprotein (MOG)<\/strong>, transmembr\u00e1nov\u00fd protein na nejsvrchn\u011bj\u0161\u00ed vrstv\u011b myelinov\u00e9 pochvy oligodendrocyt\u016f v CNS. Tyto protil\u00e1tky po\u0161kozuj\u00ed myelinov\u00e9 pochvy a vedou k charakteristick\u00e9 perivenul\u00e1rn\u00ed demyelinizaci.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Klinicky se MOGAD projevuje p\u0159edev\u0161\u00edm jako optick\u00e1 neuritida, transverz\u00e1ln\u00ed myelitida a akutn\u00ed diseminovan\u00e1 encefalomyelitida (ADEM). Onemocn\u011bn\u00ed m\u00e1 obvykle recidivuj\u00edc\u00ed pr\u016fb\u011bh a postihuje zrakov\u00fd nerv, m\u00edchu a vz\u00e1cn\u011bji i mozek. Pr\u016fm\u011brn\u00fd v\u011bk za\u010d\u00e1tku onemocn\u011bn\u00ed se pohybuje mezi 30 a 35 lety; na rozd\u00edl od NMOSD jsou \u017eeny i mu\u017ei posti\u017eeni t\u00e9m\u011b\u0159 stejn\u011b \u010dasto.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Abgrenzung_von_MOGAD_NMOSD_und_MS\"><\/span>Rozli\u0161en\u00ed mezi MOGAD, NMOSD a MS<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Funkce<\/strong><\/td><td><strong>MOGAD<\/strong><\/td><td><strong>AQP4+ NMOSD<\/strong><\/td><td><strong>Roztrou\u0161en\u00e1 skler\u00f3za<\/strong><\/td><\/tr><\/thead><tbody><tr><td>C\u00edlov\u00fd antigen<\/td><td>MOG (oligodendrocyty)<\/td><td>Aquaporin-4 (astrocyty)<\/td><td>\u017d\u00e1dn\u00e1 specifick\u00e1 autoprotil\u00e1tka<\/td><\/tr><tr><td>Izotyp protil\u00e1tky<\/td><td>IgG1 (pre)<\/td><td>IgG1 (pre)<\/td><td>Oligoklon\u00e1ln\u00ed IgG (CSF)<\/td><\/tr><tr><td>Prim\u00e1rn\u00ed po\u0161kozen\u00ed bun\u011bk<\/td><td>Oligodendrocyty\/myelin<\/td><td>Astrocyty (prim\u00e1rn\u00ed)<\/td><td>Oligodendrocyty<\/td><\/tr><tr><td>Histologie<\/td><td>Perivenul\u00e1rn\u00ed demyelinizace, CD4+<\/td><td>L\u00e9ze astrocyt\u016f, granulocyty<\/td><td>Periaxi\u00e1ln\u00ed plaky<\/td><\/tr><tr><td>Pohlav\u00ed (F:M)<\/td><td>~1:1<\/td><td>~9:1<\/td><td>~3:1<\/td><\/tr><tr><td>Aktivace komplementu<\/td><td>M\u00edrn\u00e1 (m\u00e9n\u011b MAC)<\/td><td>Strong (formace MAC)<\/td><td>N\u00edzk\u00e1<\/td><\/tr><tr><td>OKB v mozkom\u00ed\u0161n\u00edm moku<\/td><td>Vz\u00e1cn\u00e9 (&lt;10%)<\/td><td>P\u0159\u00edle\u017eitostn\u011b<\/td><td>\u010cast\u00e9 (&gt;90%)<\/td><\/tr><tr><td>Kurz<\/td><td>Recidivuj\u00edc\u00ed; \u010dasto se dob\u0159e zotav\u00ed<\/td><td>Tvarovan\u00e1 jako tah; kumuluje posti\u017een\u00ed<\/td><td>\u010casto progedientn\u00ed<\/td><\/tr><tr><td>Autorizovan\u00e9 terapie<\/td><td>\u017d\u00e1dn\u00e9 (od roku 2026)<\/td><td>Eculizumab, ublituximab, satralizumab<\/td><td>Mnoho DMT<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOG-Protein_%E2%80%93_Struktur_und_physiologische_Funktion\"><\/span>Protein MOG - struktura a fyziologick\u00e1 funkce<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">MOG (myelinov\u00fd oligodendrocyt\u00e1rn\u00ed glykoprotein) je <strong>Transmembr\u00e1nov\u00fd protein typu I<\/strong> o celkov\u00e9 d\u00e9lce 218 aminokyselin, kter\u00fd je exprimov\u00e1n v\u00fdhradn\u011b v CNS. Pat\u0159\u00ed do superrodiny imunoglobulin\u016f a s pod\u00edlem p\u0159ibli\u017en\u011b 0,01-0,05 % na celkov\u00e9m myelinov\u00e9m proteinu p\u0159edstavuje kvantitativn\u011b malou, ale imunologicky velmi v\u00fdznamnou slo\u017eku myelinov\u00e9ho pl\u00e1\u0161t\u011b.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Strukturdomanen\"><\/span>Strukturn\u00ed dom\u00e9ny<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Extracelul\u00e1rn\u00ed dom\u00e9na podobn\u00e1 Ig-V (AS 1-120): obsahuje kritickou oblast CC\u2018 smy\u010dky (Pro42, His103, Ser104) jako hlavn\u00ed epitopov\u00e9 vazebn\u00e9 m\u00edsto pro MOG-IgG.<\/li>\n\n\n\n<li>Jednopr\u016fchodov\u00e1 transmembr\u00e1nov\u00e1 \u0161roubovice: ukotvuje protein v myelinov\u00e9 membr\u00e1n\u011b.<\/li>\n\n\n\n<li>Kr\u00e1tk\u00e1 cytoplazmatick\u00e1 C-koncov\u00e1 dom\u00e9na: pravd\u011bpodobn\u011b interaguje s cytoskeletem.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Physiologische_Funktionen\"><\/span>Fyziologick\u00e9 funkce<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Adhezn\u00ed molekula: Zprost\u0159edkov\u00e1v\u00e1 struktur\u00e1ln\u00ed integritu myelinov\u00e9 pochvy, pravd\u011bpodobn\u011b t\u00edm, \u017ee zhut\u0148uje myelinov\u00e9 lamely.<\/li>\n\n\n\n<li>Interakce s C1q komplementov\u00e9ho syst\u00e9mu (fyziologick\u00e1)<\/li>\n\n\n\n<li>Interakce s nervov\u00fdm r\u016fstov\u00fdm faktorem (NGF)<\/li>\n\n\n\n<li>Receptor pro virus zard\u011bnek (klinicky relevantn\u00ed pro postinfek\u010dn\u00ed ADEM)<\/li>\n\n\n\n<li>Stabilizace mikrotubul\u016f v oligodendrocytech<\/li>\n\n\n\n<li>Exprese: Pozdn\u00ed f\u00e1ze diferenciace oligodendrocyt\u016f; pouze po po\u010d\u00e1te\u010dn\u00ed myelinizaci.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Autoprotil\u00e1tky MOG-IgG rozpozn\u00e1vaj\u00ed p\u0159edev\u0161\u00edm <strong>Konforma\u010dn\u00ed epitopy<\/strong> extracelul\u00e1rn\u00ed dom\u00e9ny. Proto\u017ee je MOG vystaven na nejzevn\u011bj\u0161\u00edm povrchu myelinov\u00e9 pochvy, je p\u0159\u00edmo p\u0159\u00edstupn\u00fd cirkuluj\u00edc\u00edm protil\u00e1tk\u00e1m a imunitn\u00edm komplex\u016fm, co\u017e je rozhoduj\u00edc\u00ed rozd\u00edl oproti intracelul\u00e1rn\u00edm antigen\u016fm.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pathogenese_und_Immunpathologie\"><\/span>Patogeneze a imunopatologie<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Patogeneze MOGAD je v\u00edcestup\u0148ov\u00fd proces zahrnuj\u00edc\u00ed aktivaci perifern\u00edho imunitn\u00edho syst\u00e9mu, migraci p\u0159es hematoencefalickou bari\u00e9ru (BBB) a lok\u00e1ln\u00ed efektorov\u00e9 mechanismy v CNS. Samotn\u00e9 T-lymfocyty ani B-lymfocyty nejsou dostate\u010dn\u011b patogenn\u00ed, onemocn\u011bn\u00ed zp\u016fsobuje synergick\u00e1 interakce obou ramen adaptivn\u00edho imunitn\u00edho syst\u00e9mu.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Trigger_und_initiale_Aktivierung\"><\/span>Spou\u0161t\u011bn\u00ed a po\u010d\u00e1te\u010dn\u00ed aktivace<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Hlavn\u00edmi po\u010d\u00e1te\u010dn\u00edmi spou\u0161t\u011b\u010di jsou <strong>Infekce<\/strong> diskutovalo se o: Infek\u010dn\u00ed prodrom byl prok\u00e1z\u00e1n u 37-70 % pacient\u016f s MOGAD (\u010dast\u011bji ne\u017e u NMOSD s 15-35 %). Mechanismy zahrnuj\u00ed:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Molekul\u00e1rn\u00ed mimikry - epitopy patogen\u016f jsou strukturn\u011b podobn\u00e9 oblasti CC\u2018 smy\u010dky MOG, nap\u0159. sekvence SARS-CoV-2 nebo viry zard\u011bnek.<\/li>\n\n\n\n<li>Bystanderova aktivace - nespecifick\u00e1 z\u00e1n\u011btliv\u00e1 reakce aktivuje sp\u00edc\u00ed autoreaktivn\u00ed lymfocyty.<\/li>\n\n\n\n<li>Polyklon\u00e1ln\u00ed aktivace B-bun\u011bk mikrobi\u00e1ln\u00edmi superantigeny<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Genetick\u00e1 predispozice hraje ur\u010ditou roli, ale specifick\u00e9 rizikov\u00e9 haplotypy nebyly jednozna\u010dn\u011b identifikov\u00e1ny. Na rozd\u00edl od RS nebyly pops\u00e1ny \u017e\u00e1dn\u00e9 konzistentn\u00ed HLA asociace.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"T-Zell-vermittelte_Pathogenese\"><\/span>Patogeneze zprost\u0159edkovan\u00e1 T-bu\u0148kami<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MOG specifick\u00e9 CD4+ T bu\u0148ky jsou pro patogenezi MOGAD z\u00e1sadn\u00ed. U zv\u00ed\u0159ec\u00edch model\u016f (EAE) nejsou samotn\u00e9 protil\u00e1tky patogenn\u00ed; vy\u017eaduj\u00ed encefalitogenn\u00ed T-bu\u0148ky jako koefektory. Cesta CD4+ zahrnuje n\u011bkolik f\u00e1z\u00ed:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_1_%E2%80%93_Periphere_Aktivierung\"><\/span>F\u00e1ze 1 - perifern\u00ed aktivace<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Peptidy MOG jsou produkov\u00e1ny antigen-prezentuj\u00edc\u00edmi bu\u0148kami (APC) prost\u0159ednictv\u00edm <strong>Molekuly MHC-II<\/strong> naivn\u00edm CD4+ T bu\u0148k\u00e1m. Za zm\u00ednku stoj\u00ed: <em>Peptidy MOG se mohou p\u0159\u00edmo v\u00e1zat na perifern\u00ed molekuly MHC II.<\/em>, bez dal\u0161\u00edho zpracov\u00e1n\u00ed. To by mohlo vysv\u011btlovat zapojen\u00ed perifern\u00edho nervov\u00e9ho syst\u00e9mu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Podskupiny efektorov\u00fdch bun\u011bk, kter\u00e9 mohou nez\u00e1visle na sob\u011b vyvolat EAE, jsou tyto. <strong>Th1, Th17 a Th9<\/strong>. Bu\u0148ky Th17 jsou pro MOGAD obzvl\u00e1\u0161t\u011b d\u016fle\u017eit\u00e9, proto\u017ee cytokiny Th17 (IL-17, IL-21) jsou b\u011bhem epizod st\u0159ihu v\u00fdrazn\u011b zv\u00fd\u0161en\u00e9.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_2_%E2%80%93_BHS-Penetration\"><\/span>F\u00e1ze 2 - pronik\u00e1n\u00ed BHS<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Aktivovan\u00e9 CD4+ T-lymfocyty exprimuj\u00ed specifick\u00e9 adhezn\u00ed molekuly (integriny, selektiny) a chemokinov\u00e9 receptory (zejm\u00e9na <strong>CCR6<\/strong>), kter\u00e9 jim umo\u017e\u0148uj\u00ed vstup do CNS. CCR6+ Th17 bu\u0148ky se v\u00e1\u017eou na CCL20, kter\u00fd je konstitutivn\u011b exprimov\u00e1n v choroid\u00e1ln\u00edm plexu, a jeho prost\u0159ednictv\u00edm vstupuj\u00ed do subarachnoid\u00e1ln\u00edho prostoru.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Matrixov\u00e9 metaloprotein\u00e1zy (MMP-2, MMP-9)<br>Degradace baz\u00e1ln\u00ed membr\u00e1ny BBB<\/li>\n\n\n\n<li>NET (extracelul\u00e1rn\u00ed lapa\u010de neutrofil\u016f)<br>Poskytuj\u00ed kostimula\u010dn\u00ed sign\u00e1ly pro T-bu\u0148ky v inicia\u010dn\u00ed f\u00e1zi.<\/li>\n\n\n\n<li>Trombocyty<br>Podpora proliferace CD4+ T bun\u011bk a jejich diferenciace na Th1\/Th17 prost\u0159ednictv\u00edm cytokin\u016f a adhezn\u00edch molekul.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_3_%E2%80%93_Perivaskulare_Reaktivierung\"><\/span>F\u00e1ze 3 - Perivaskul\u00e1rn\u00ed reaktivace<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">V perivaskul\u00e1rn\u00edm a subarachnoid\u00e1ln\u00edm prostoru jsou T-bu\u0148ky specifick\u00e9 pro MOG reaktivov\u00e1ny m\u00edstn\u00edmi APC s MOG (mikroglie, dendritick\u00e9 bu\u0148ky). Tato reaktivace spou\u0161t\u00ed vlastn\u00ed z\u00e1n\u011btlivou kask\u00e1du: Proz\u00e1n\u011btliv\u00e9 cytokiny, n\u00e1bor dal\u0161\u00edch leukocyt\u016f a po\u0161kozen\u00ed oligodendrocyt\u016f.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"B-Zell-_und_Antikorper-vermittelte_Pathogenese\"><\/span>Patogeneze zprost\u0159edkovan\u00e1 B-bu\u0148kami a protil\u00e1tkami<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">MOG specifick\u00e9 B bu\u0148ky a plazmatick\u00e9 bu\u0148ky jsou hlavn\u00edmi producenty patogenn\u00edch autoprotil\u00e1tek IgG1. \u00daloha B bun\u011bk v\u0161ak p\u0159esahuje r\u00e1mec produkce protil\u00e1tek:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Prezentace antigenu - B-bu\u0148ky mohou v\u00e1zat konforma\u010dn\u00ed epitopy MOG (pro42, his103, ser104 smy\u010dky CC\u2018) prost\u0159ednictv\u00edm sv\u00e9ho BCR a p\u016fsobit jako APC pro T-bu\u0148ky.<\/li>\n\n\n\n<li>Podpora diferenciace Th17 - B bu\u0148ky vylu\u010duj\u00ed IL-6, kter\u00fd spolu s TGF-\u03b2 podporuje diferenciaci Th17.<\/li>\n\n\n\n<li>Aktivace signalizace MAPK a AKT - vazba BCR na MOG aktivuje tyto sign\u00e1ln\u00ed dr\u00e1hy intracelul\u00e1rn\u011b.<\/li>\n\n\n\n<li>Zv\u00fd\u0161en\u00ed intracelul\u00e1rn\u00edho v\u00e1pn\u00edku - vede k aktivaci sign\u00e1ln\u00edch kask\u00e1d spojen\u00fdch se stresem.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">V\u011bt\u0161ina protil\u00e1tek MOG-IgG se tvo\u0159\u00ed na periferii (oligoklon\u00e1ln\u00ed p\u00e1sy v mozkom\u00ed\u0161n\u00edm moku pouze v ~10 % p\u0159\u00edpad\u016f, pro srovn\u00e1n\u00ed: RS ~90 %). Protil\u00e1tky jsou <strong>bivalentn\u00ed vazba<\/strong> na MOG se ob\u011b ramena Fab v\u00e1\u017eou sou\u010dasn\u011b na dv\u011b sousedn\u00ed molekuly MOG. To vede k m\u00e9n\u011b \u00fa\u010dinn\u00e9mu n\u00e1boru C1q ve srovn\u00e1n\u00ed s monovalentn\u00ed vazbou AQP4-IgG v NMOSD.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Molekulare_Signalwege_und_Effektormechanismen\"><\/span>Molekul\u00e1rn\u00ed sign\u00e1ln\u00ed dr\u00e1hy a efektorov\u00e9 mechanismy<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_1_%E2%80%93_Klassischer_Komplementweg_CDC\"><\/span>Sign\u00e1ln\u00ed dr\u00e1ha 1 - klasick\u00e1 komplementov\u00e1 dr\u00e1ha (CDC)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pokud se MOG-IgG1 (a MOG-IgG3) nav\u00e1\u017ee na oligodendrocyt\u00e1rn\u00ed MOG, dojde k vytvo\u0159en\u00ed tzv. <strong>klasick\u00e1 dopl\u0148kov\u00e1 trasa<\/strong> jsou aktivov\u00e1ny. Aktivace komplementu u MOGAD je v\u0161ak slab\u0161\u00ed ne\u017e u AQP4+ NMOSD:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Vazba C1q na Fc \u010d\u00e1st nav\u00e1zan\u00fdch IgG1 protil\u00e1tek \u2192 aktivace C1r a C1s<\/li>\n\n\n\n<li>\u0160t\u011bpen\u00ed C4 \u2192 C4a + C4b; C4b + C2 \u2192 C3 konvert\u00e1za (C4b2a)<\/li>\n\n\n\n<li>\u0160t\u011bpen\u00ed C3 \u2192 C3a (anafylatoxin) + C3b (opsonin)<\/li>\n\n\n\n<li>C3b \u2192 C5 konvert\u00e1za \u2192 \u0161t\u011bpen\u00ed C5 \u2192 C5a (siln\u00fd anafylatoxin) + C5b<\/li>\n\n\n\n<li>C5b + C6, C7, C8, C9 \u2192 membr\u00e1nov\u00fd \u00fato\u010dn\u00fd komplex (MAC, C5b-9): P\u0159\u00edm\u00e1 l\u00fdza oligodendrocyt\u016f<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">D\u016fle\u017eit\u00e9: V mozkom\u00ed\u0161n\u00edm moku pacient\u016f s MOGAD jsou v\u00fdznamn\u011b zv\u00fd\u0161eny C3a a C5a (srovnateln\u00e9 s AQP4+ NMOSD), ale komplex MAC (C5b-9) nen\u00ed v\u00fdznamn\u011b zv\u00fd\u0161en. <strong>v\u00fdrazn\u011b ni\u017e\u0161\u00ed<\/strong> ne\u017e v NMOSD. To je zp\u016fsobeno bivalentn\u00ed vazbou IgG, kter\u00e1 je m\u00e9n\u011b \u00fa\u010dinn\u00e1 pro shlukov\u00e1n\u00ed C1q, a relativn\u011b n\u00edzkou hustotou regul\u00e1tor\u016f komplementu na oligodendrocytech (m\u00e9n\u011b CR1, MCP, HRF ne\u017e na jin\u00fdch typech bun\u011bk).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_2_%E2%80%93_Fc%CE%B3-Rezeptor-Weg_FcR-vermittelt\"><\/span>Sign\u00e1ln\u00ed dr\u00e1ha 2 - dr\u00e1ha receptoru Fc\u03b3 (zprost\u0159edkovan\u00e1 FcR)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">V\u00fdzkum LMU (Mader, Kawakami, Meinl, 2024 PNAS) uk\u00e1zal, \u017ee mechanismy zprost\u0159edkovan\u00e9 receptorem Fc\u03b3 (Fc\u03b3R). <strong>na p\u0159ibli\u017en\u011b 50 % po\u0161kozen\u00ed myelinu<\/strong> a jsou tedy rovnocenn\u00e9 aktivaci komplementu:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fc\u03b3RIII<\/strong> (<strong>CD16<\/strong>) na bu\u0148ky NK a makrof\u00e1gy<br>V\u00e1\u017ee Fc \u010d\u00e1st IgG1 v\u00e1zan\u00e9ho na MOG \u2192 ADCC (bun\u011b\u010dn\u00e1 cytotoxicita z\u00e1visl\u00e1 na protil\u00e1tk\u00e1ch)<\/li>\n\n\n\n<li><strong>Fc\u03b3RI\/II\/III<\/strong> na makrof\u00e1gy a monocyty<br>Fagocyt\u00f3za fragment\u016f oligodendrocyt\u016f opsonizovan\u00fdch MOG (ADCP)<\/li>\n\n\n\n<li>Rozhoduj\u00edc\u00ed: druh\u00fd patomechanismus FcR<br>Zv\u00fd\u0161en\u00ed aktivace T-bun\u011bk prob\u00edh\u00e1 v\u00fdhradn\u011b prost\u0159ednictv\u00edm Fc receptor\u016f, NE cestou komplementu.<\/li>\n\n\n\n<li><strong>Fc\u03b3R<\/strong> na dendritick\u00fdch bu\u0148k\u00e1ch<br>Usnadn\u011bn\u00ed zpracov\u00e1n\u00ed a prezentace oligodendrocyt\u00e1rn\u00edch antigen\u016f s obsahem MOG-IgG T-bu\u0148k\u00e1m specifick\u00fdm pro MOG.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Klinick\u00e9 d\u016fsledky: Vzhledem k tomu, \u017ee existuj\u00ed dv\u011b nez\u00e1visl\u00e9 patogenetick\u00e9 cesty, mus\u00ed b\u00fdt terapeutick\u00e9 p\u0159\u00edstupy <strong>Oba mechanismy<\/strong> aby bylo dosa\u017eeno maxim\u00e1ln\u00ed \u00fa\u010dinnosti.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_3_%E2%80%93_IL-6JAK-STAT3-Weg\"><\/span>Sign\u00e1ln\u00ed dr\u00e1ha 3 - dr\u00e1ha IL-6\/JAK-STAT3<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">IL-6 je \u00fast\u0159edn\u00edm medi\u00e1torem imunopatogeneze MOGAD a p\u016fsob\u00ed na n\u011bkolika \u00farovn\u00edch:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">IL-6 se v\u00e1\u017ee na sv\u016fj receptor (komplex IL-6R\u03b1\/gp130), co\u017e vede k jeho vzniku. <strong>Fosforylace JAK1\/2<\/strong> vede. To aktivuje p\u0159edev\u0161\u00edm <strong>STAT3<\/strong>, kter\u00fd slou\u017e\u00ed jako transkrip\u010dn\u00ed faktor pro:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Diferenciace Th17<\/strong><br>IL-6 + TGF-\u03b2 \u2192 exprese ROR\u03b3t \u2192 produkce IL-17A\/F; IL-6 + IL-23 \u2192 udr\u017een\u00ed fenotypu Th17<\/li>\n\n\n\n<li><strong>Folikul\u00e1rn\u00ed pomocn\u00e9 T-bu\u0148ky<\/strong> (<strong>Tfh<\/strong>)<br>IL-6 \u2192 STAT3 \u2192 exprese Bcl6 \u2192 dozr\u00e1v\u00e1n\u00ed B bun\u011bk germin\u00e1ln\u00edho centra a zm\u011bna t\u0159\u00eddy IgG<\/li>\n\n\n\n<li><strong>Dozr\u00e1v\u00e1n\u00ed B-bun\u011bk na plazmatick\u00e9 bu\u0148ky<\/strong><br>IL-6 podporuje diferenciaci prost\u0159ednictv\u00edm osy STAT3\/Blimp-1<\/li>\n\n\n\n<li><strong>Potla\u010den\u00ed funkce Treg<\/strong><br>IL-6 inhibuje expresi FoxP3, co\u017e posouv\u00e1 rovnov\u00e1hu Treg\/Th17 sm\u011brem k z\u00e1n\u011btu.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Terapeutick\u00fd v\u00fdznam: Blok\u00e1da IL-6 (nap\u0159. tocilizumab, satralizumab) tento cyklus p\u0159eru\u0161\u00ed. <strong><em>Satralizumab<\/em><\/strong> (anti-IL-6R) je v sou\u010dasn\u00e9 dob\u011b zkoum\u00e1n ve studii f\u00e1ze 3 METEOROID pro MOGAD.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_4_%E2%80%93_MAPK-_und_AKT-Signalwege_B-Zellen\"><\/span>Sign\u00e1ln\u00ed dr\u00e1ha 4 - sign\u00e1ln\u00ed dr\u00e1hy MAPK a AKT (B bu\u0148ky)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Vazba BCR na konforma\u010dn\u00ed epitopy MOG aktivovan\u00e9 v B bu\u0148k\u00e1ch:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cesta MAPK<\/strong> (<strong>MEK\/ERK<\/strong>)<br>Podpora proliferace a diferenciace B-bun\u011bk<\/li>\n\n\n\n<li><strong>Dr\u00e1ha PI3K\/AKT<\/strong><br>P\u0159e\u017e\u00edv\u00e1n\u00ed bun\u011bk a diferenciace B bun\u011bk v plazmatick\u00e9 bu\u0148ky<\/li>\n\n\n\n<li><strong>P\u0159\u00edliv v\u00e1pn\u00edku<\/strong><br>Aktivace osy kalcineurin\/NFAT \u2192 produkce cytokin\u016f<\/li>\n\n\n\n<li><strong>Aktivace NK bun\u011bk<\/strong><br>Vazba BCR-MOG indukuje cytotoxicitu zprost\u0159edkovanou NK bu\u0148kami<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalweg_5_%E2%80%93_Th17-Zytokin-Netzwerk_im_ZNS\"><\/span>Sign\u00e1ln\u00ed dr\u00e1ha 5 - s\u00ed\u0165 cytokin\u016f Th17 v CNS<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">V CNS udr\u017euj\u00ed bu\u0148ky Th17 z\u00e1n\u011btliv\u00e9 prost\u0159ed\u00ed prost\u0159ednictv\u00edm mnoha medi\u00e1tor\u016f:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IL-17A a IL-17F<\/strong><br>Aktivace astrocyt\u016f a mikroglie; uvol\u0148ov\u00e1n\u00ed chemokin\u016f (CXCL-1\/5\/8), kter\u00e9 rekrutuj\u00ed neutrofily.<\/li>\n\n\n\n<li><strong>IL-21<\/strong> (auto- a parakrinn\u00ed)<br>Zvy\u0161uje diferenciaci Th17; podporuje diferenciaci B-bun\u011bk a zm\u011bnu t\u0159\u00eddy IgG (zejm\u00e9na IgG1).<\/li>\n\n\n\n<li><strong>IL-22<\/strong><br>Dysregulace integrity BBB<\/li>\n\n\n\n<li><strong>GM-CSF<\/strong> (<strong>prost\u0159ednictv\u00edm IL-23<\/strong>)<br>Aktivuje mikroglie a makrof\u00e1gy, zvy\u0161uje lok\u00e1ln\u00ed demyelinizaci<\/li>\n\n\n\n<li><strong>CXCL13<\/strong><br>Chemotaxe B bun\u011bk v perivaskul\u00e1rn\u00edch prostorech \u2192 lok\u00e1ln\u00ed produkce protil\u00e1tek<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signalwege_%E2%80%93_Ubersicht\"><\/span>Sign\u00e1ln\u00ed dr\u00e1hy - p\u0159ehled<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Cesta sign\u00e1lu<\/strong><\/td><td><strong>Kl\u00ed\u010dov\u00e9 molekuly<\/strong><\/td><td><strong>Efekt<\/strong><\/td><td><strong>Terapeutick\u00e9 c\u00edle<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Klasick\u00e1 dopl\u0148kov\u00e1 trasa<\/td><td>C1q, C3, C5, MAC (C5b-9)<\/td><td>P\u0159\u00edm\u00e1 l\u00fdza oligodendrocyt\u016f<\/td><td>Inhibitory C5 (eculizumab), inhibitory C3<\/td><\/tr><tr><td>Cesta Fc\u03b3R (ADCC\/ADCP)<\/td><td>Fc\u03b3RI\/II\/III, NK bu\u0148ky, makrof\u00e1gy<\/td><td>Cytotoxicita, fagocyt\u00f3za, potenciace T-bun\u011bk<\/td><td>Inhibitory FcRn (degradace IgG), blok\u00e1da FcR<\/td><\/tr><tr><td>IL-6\/JAK-STAT3<\/td><td>IL-6, IL-6R\u03b1, gp130, JAK1\/2, STAT3, ROR\u03b3t<\/td><td>diferenciace Th17, zr\u00e1n\u00ed B-bun\u011bk, produkce IgG<\/td><td>Anti-IL-6R (tocilizumab, satralizumab)<\/td><\/tr><tr><td>PI3K\/AKT\/MAPK (B bu\u0148ky)<\/td><td>BTK, PI3K, AKT, ERK, NFAT<\/td><td>aktivace B-bun\u011bk, zr\u00e1n\u00ed plazmatick\u00fdch bun\u011bk<\/td><td>Inhibitory BTK (ibrutinib, tolebrutinib)<\/td><\/tr><tr><td>S\u00ed\u0165 cytokin\u016f Th17<\/td><td>IL-17, IL-21, IL-22, GM-CSF, CXCL13<\/td><td>Po\u0161kozen\u00ed BBB, n\u00e1bor leukocyt\u016f, demyelinizace<\/td><td>Anti-IL-17, Anti-IL-21<\/td><\/tr><tr><td>Recyklace FcRn-IgG<\/td><td>FcRn (novorozeneck\u00fd Fc receptor)<\/td><td>Prodlou\u017een\u00fd polo\u010das rozpadu IgG<\/td><td>Anti-FcRn (rozanolixizumab)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Relevante_Rezeptoren_und_Zielmolekule\"><\/span>Relevantn\u00ed receptory a c\u00edlov\u00e9 molekuly<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOG_selbst_als_Zielstruktur_kein_klassischer_Rezeptor\"><\/span>samotn\u00fd MOG jako c\u00edlov\u00e1 struktura (nikoli klasick\u00fd receptor)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">V p\u0159\u00edpad\u011b MOGAD funguje protein MOG jako antigen, nikoli jako sign\u00e1ln\u00ed receptor. Nicm\u00e9n\u011b n\u00e1sleduj\u00edc\u00ed interakce jsou patofyziologicky v\u00fdznamn\u00e9:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vazba C1q<\/strong><br>MOG m\u016f\u017ee fyziologicky v\u00e1zat C1q, co\u017e vede k aktivaci komplementu v p\u0159\u00edpad\u011b patologick\u00e9ho pokryt\u00ed protil\u00e1tkami.<\/li>\n\n\n\n<li><strong>DC-SIGN (CD209)<\/strong><br>Lektinov\u00fd receptor na dendritick\u00fdch bu\u0148k\u00e1ch; m\u016f\u017ee v\u00e1zat MOG a p\u0159isp\u00edvat k prezentaci antigenu.<\/li>\n\n\n\n<li><strong>Receptor viru zard\u011bnek<\/strong>_<br>MOG slou\u017e\u00ed jako vstupn\u00ed molekula pro viry zard\u011bnek, co\u017e by mohlo vysv\u011btlovat postinfek\u010dn\u00ed ADEM u d\u011bt\u00ed.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Fc%CE%B3-Rezeptoren_Fc%CE%B3R\"><\/span>Receptory Fc\u03b3 (Fc\u03b3R)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Receptory Fc\u03b3 na imunitn\u00edch bu\u0148k\u00e1ch jsou \u00fast\u0159edn\u00edmi efektory po\u0161kozen\u00ed zprost\u0159edkovan\u00e9ho IgG1:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fc\u03b3RI (CD64)<\/strong><br>Vysok\u00e1 afinita, na makrof\u00e1gy a dendritick\u00e9 bu\u0148ky; zprost\u0159edkov\u00e1n\u00ed ADCP a prezentace antigenu<\/li>\n\n\n\n<li><strong>Fc\u03b3RIII (CD16)<\/strong><br>N\u00edzk\u00e1 afinita, na NK bu\u0148k\u00e1ch; hlavn\u00ed medi\u00e1tor ADCC proti oligodendrocyt\u016fm opsonizovan\u00fdm MOG<\/li>\n\n\n\n<li><strong>Fc\u03b3RIIA\/B (CD32A\/B)<\/strong><br>Aktivace nebo inhibice; modulace aktivace B-bun\u011bk a fagocyt\u00f3zy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neonataler_Fc-Rezeptor_FcRn\"><\/span>Neonat\u00e1ln\u00ed Fc receptor (FcRn)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">FcRn (komplex \u03b22m\/FcRn-\u03b1) je zodpov\u011bdn\u00fd za intracelul\u00e1rn\u00ed recyklaci protil\u00e1tek IgG. V\u00e1\u017ee IgG v okyselen\u00fdch endozomech (pH 6,0) a zabra\u0148uje jeho lyzozom\u00e1ln\u00ed degradaci, \u010d\u00edm\u017e prodlu\u017euje polo\u010das rozpadu IgG na p\u0159ibli\u017en\u011b 21 dn\u00ed.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>U MOGAD zp\u016fsobuje FcRn trvalou cirkulaci patogenn\u00edho MOG-IgG1.<\/li>\n\n\n\n<li>Terapeutick\u00e1 blok\u00e1da v d\u016fsledku <em>Rozanolixizumab<\/em> (anti-FcRn IgG4): Vnucuje lysozom\u00e1ln\u00ed degradaci IgG a sni\u017euje plazmatick\u00fd IgG o ~50%<\/li>\n\n\n\n<li>Exprese FcRn - epiteli\u00e1ln\u00ed bu\u0148ky, endoteli\u00e1ln\u00ed bu\u0148ky, monocyty, hepatocyty<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"IL-6-Rezeptor_IL-6R%CE%B1_gp130\"><\/span>Receptor IL-6 (IL-6R\u03b1 \/ gp130)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Receptor IL-6 se skl\u00e1d\u00e1 z \u03b1-podjednotky v\u00e1zaj\u00edc\u00ed ligand (IL-6R\u03b1, CD126) a sign\u00e1ln\u00edho ko-receptoru gp130 (IL-6R\u03b2, CD130). Dva zp\u016fsoby signalizace:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Klasick\u00e1 signalizace<\/strong><br>Membr\u00e1nov\u011b v\u00e1zan\u00fd IL-6R\u03b1 na T-bu\u0148k\u00e1ch, B-bu\u0148k\u00e1ch, monocytech \u2192 komplex IL-6\/IL-6R\u03b1\/gp130 \u2192 JAK1\/2 \u2192 STAT3, STAT1, MAPK, PI3K\/AKT<\/li>\n\n\n\n<li><strong>Trans signalizace<\/strong><br>Rozpustn\u00fd IL-6R\u03b1 (sIL-6R) v\u00e1\u017ee IL-6 a aktivuje gp130 i na bu\u0148k\u00e1ch bez membr\u00e1nov\u011b v\u00e1zan\u00e9ho IL-6R\u03b1 (nap\u0159. endotelov\u00e9 bu\u0148ky BBB).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Relevantn\u00ed n\u00e1sledn\u00e9 \u00fa\u010dinky: Exprese ROR\u03b3t (Th17), Bcl-6 (Tfh a germin\u00e1ln\u00ed centra), Blimp-1 (plazmatick\u00e9 bu\u0148ky), potla\u010den\u00ed FoxP3 (Treg).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"T-Zell-Rezeptor_TCR_und_Kostimulationsmolekule\"><\/span>T-bun\u011b\u010dn\u00fd receptor (TCR) a kostimula\u010dn\u00ed molekuly<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>peptidov\u00fd komplex TCR\/MHC-II-MOG<\/strong><br>Centr\u00e1ln\u00ed aktiva\u010dn\u00ed osa pro MOG specifick\u00e9 CD4+ T bu\u0148ky<\/li>\n\n\n\n<li><strong>CD28\/B7<\/strong><br>Kostimulace b\u011bhem aktivace T-bun\u011bk<\/li>\n\n\n\n<li><strong>Osa CCR6\/CCL20<\/strong><br>CCR6 na bu\u0148k\u00e1ch Th17 v\u00e1\u017ee CCL20 v choroid\u00e1ln\u00edm plexu \u2192 vstup do CNS<\/li>\n\n\n\n<li><strong>CXCR3\/CXCL10<\/strong><br>Chemotaxe Th1 bun\u011bk v oblastech z\u00e1n\u011btu<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Komplementrezeptoren\"><\/span>Receptory komplementu<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>C1qR<\/strong><br>Zprost\u0159edkov\u00e1v\u00e1 vazbu C1q na imunitn\u00ed komplexy na membr\u00e1n\u00e1ch oligodendrocyt\u016f.<\/li>\n\n\n\n<li><strong>C3aR <\/strong>a<strong> C5aR1 (CD88)<\/strong><br>Anafylatoxinov\u00e9 receptory na mikroglie\/makrof\u00e1gy \u2192 Proz\u00e1n\u011btliv\u00e1 aktivace<\/li>\n\n\n\n<li><strong>Regul\u00e1tory komplementu na oligodendrocytech<\/strong><br>CR1 (CD35), MCP (CD46), HRF (CD59) jsou na oligodendrocytech m\u00e1lo exprimov\u00e1ny, co\u017e je \u010din\u00ed n\u00e1chyln\u011bj\u0161\u00edmi k po\u0161kozen\u00ed komplementem ne\u017e nap\u0159. astrocyty.<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Histopathologie_und_ZNS-Lasionsmuster\"><\/span>Histopatologie a obraz l\u00e9z\u00ed CNS<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">L\u00e9ze MOGAD se histopatologicky z\u00e1sadn\u011b li\u0161\u00ed od RS a NMOSD:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Periven\u00f3zn\u00ed demyelinizace<\/strong><br>L\u00e9ze se tvo\u0159\u00ed koncentricky kolem mal\u00fdch \u017eil (periven\u00f3zn\u00ed vzor), nikoliv periaxi\u00e1ln\u011b jako u RS. Typick\u00e9 \u201acentr\u00e1ln\u00ed \u017eiln\u00ed znamen\u00ed\u2018 pro RS nen\u00ed na MRI p\u0159\u00edtomno.<\/li>\n\n\n\n<li><strong>Infiltr\u00e1t CD4+ T-bun\u011bk<\/strong><br>Dominantn\u00ed z\u00e1n\u011btliv\u00e9 bu\u0148ky jsou CD4+ T-lymfocyty a makrof\u00e1gy, m\u00e9n\u011b neutrofil\u016f a t\u00e9m\u011b\u0159 \u017e\u00e1dn\u00e9 eozinofiln\u00ed granulocyty (na rozd\u00edl od AQP4+ NMOSD).<\/li>\n\n\n\n<li><strong>Po\u0161kozen\u00ed oligodendrocyt\u016f<\/strong> (prim\u00e1rn\u00ed)<br>Na rozd\u00edl od NMOSD, kde jsou prim\u00e1rn\u011b po\u0161kozeny astrocyty, je MOGAD charakterizov\u00e1na degenerac\u00ed oligodendrocyt\u016f.<\/li>\n\n\n\n<li><strong>Depozice C9neo<\/strong><br>Detekce MAC (termin\u00e1ln\u00edho komplexu komplementu) v l\u00e9z\u00edch, i kdy\u017e slab\u0161\u00ed ne\u017e u NMOSD<\/li>\n\n\n\n<li><strong>Relativn\u00ed zachov\u00e1n\u00ed axon\u016f<\/strong><br>U akutn\u00edch z\u00e1chvat\u016f je axon\u00e1ln\u00ed po\u0161kozen\u00ed \u010dasto m\u00e9n\u011b z\u00e1va\u017en\u00e9 ne\u017e u RS, co\u017e vysv\u011btluje \u010dasto dobr\u00e9 klinick\u00e9 zotaven\u00ed.<\/li>\n\n\n\n<li><strong>Kortik\u00e1ln\u00ed l\u00e9ze<\/strong><br>Leptomeninge\u00e1ln\u00ed z\u00e1n\u011bt a kortik\u00e1ln\u00ed demyelinizace (\u010dast\u00e9 u varianty ADEM).<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Klinische_Manifestationen_und_Phanotypen\"><\/span>Klinick\u00e9 projevy a fenotypy<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD je klinicky heterogenn\u00ed. D\u016fle\u017eit\u00e9 fenotypy:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Fenotyp<\/strong><\/td><td><strong>Frekvence<\/strong><\/td><td><strong>Klinick\u00e9 rysy<\/strong><\/td><td><strong>Specializace MRI<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Z\u00e1n\u011bt zrakov\u00e9ho nervu (ON)<\/td><td>Nejb\u011b\u017en\u011bj\u0161\u00ed (p\u0159ibli\u017en\u011b 50%)<\/td><td>\u010casto oboustrann\u00e1, ztr\u00e1ta zraku, retrobulb\u00e1rn\u00ed, bolestiv\u00e9 pohyby o\u010d\u00ed. o\u010dn\u00ed pohyby<\/td><td>Dlouh\u00e9 posti\u017een\u00ed zrakov\u00e9ho nervu, perinervn\u00ed akumulace kontrastn\u00ed l\u00e1tky<\/td><\/tr><tr><td>P\u0159\u00ed\u010dn\u00e1 myelitida<\/td><td>P\u0159ibli\u017en\u011b 30%<\/td><td>Longitudin\u00e1ln\u00ed myelitida (LETM), senzorick\u00e9\/motorick\u00e9 poruchy, poruchy mo\u010dov\u00e9ho m\u011bch\u00fd\u0159e<\/td><td>Pod\u00e9ln\u00e9 T2 l\u00e9ze, H2 syndrom (\u201a\u010do\u010dkovit\u00fd\u2018)<\/td><\/tr><tr><td>ADEM<\/td><td>Nej\u010dast\u011bj\u0161\u00ed projevy u d\u011bt\u00ed<\/td><td>Encefalopatie, polyfok\u00e1ln\u00ed neurologick\u00e9 deficity deficity<\/td><td>Oboustrann\u00e9, velkoobjemov\u00e9 T2 l\u00e9ze, tak\u00e9 baz\u00e1ln\u00ed ganglia<\/td><\/tr><tr><td>Encefalitida mozkov\u00e9ho kmene<\/td><td>P\u0159ibli\u017en\u011b 15%<\/td><td>Diplopie, ataxie, area postrema syndrom (\u0161kytavka, zvracen\u00ed)<\/td><td>Mozkov\u00fd kmen \/ moze\u010dkov\u00e9 T2 l\u00e9ze<\/td><\/tr><tr><td>Kortik\u00e1ln\u00ed encefalitida<\/td><td>Vz\u00e1cn\u011bj\u0161\u00ed<\/td><td>Epileptick\u00e9 z\u00e1chvaty, zmatenost<\/td><td>Zm\u011bny korov\u00e9 signalizace FLAIR<\/td><\/tr><tr><td>CRION<\/td><td>Vz\u00e1cn\u011bj\u0161\u00ed<\/td><td>Chronick\u00fd recidivuj\u00edc\u00ed z\u00e1n\u011bt. optick\u00e1 neuropatie<\/td><td>Trval\u00e9 po\u0161kozen\u00ed zrakov\u00e9ho nervu<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Diagnostik\"><\/span>Diagnostika<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">Diagnostick\u00e1 krit\u00e9ria (Banwell et al, <em>Lancet Neurology<\/em> 2023): <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">(1) Detekce MOG-IgG v s\u00e9ru nebo mozkom\u00ed\u0161n\u00edm moku pomoc\u00ed bun\u011b\u010dn\u00e9ho testu (CBA)<br>(2) odpov\u00eddaj\u00edc\u00ed klinick\u00fd fenotyp<br>(3) Vylou\u010den\u00ed alternativn\u00edch diagn\u00f3z.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bun\u011b\u010dn\u00fd imunofluorescen\u010dn\u00ed test (CBA)<\/strong><br>s p\u0159irozen\u011b slo\u017een\u00fdm, membr\u00e1nov\u011b v\u00e1zan\u00fdm MOG (bu\u0148ky HEK293 transfekovan\u00e9 lidsk\u00fdm MOG); detekuje epitopy z\u00e1visl\u00e9 na konformaci.<\/li>\n\n\n\n<li><strong>ELISA a line\u00e1rn\u00ed\/prou\u017ekov\u00e9 bloty<\/strong><br>Nespolehliv\u00e9 pro MOGAD, proto\u017ee jsou rozpozn\u00e1ny line\u00e1rn\u00ed epitopy.<\/li>\n\n\n\n<li><strong>Podt\u0159\u00eddy IgG<\/strong><br>P\u0159edev\u0161\u00edm IgG1; p\u0159\u00edle\u017eitostn\u011b IgG2, IgG3, IgG4. V\u00fdhradn\u00ed pozitivita IgG3 je diagnostick\u00fdm \u00faskal\u00edm (Jarius 2024).<\/li>\n\n\n\n<li><strong>Titrov\u00e1 kinetika<\/strong><br>Trvale vysok\u00e9 titry koreluj\u00ed s rizikem relapsu; \u010dasto klesaj\u00edc\u00ed p\u0159i monof\u00e1zick\u00e9m pr\u016fb\u011bhu<\/li>\n\n\n\n<li><strong>Lik\u00e9r<\/strong><br>Mo\u017en\u00e1 pleocyt\u00f3za; oligoklon\u00e1ln\u00ed p\u00e1sy vz\u00e1cn\u00e9 (&lt;10 %), intratek\u00e1ln\u00ed synt\u00e9za IgG vz\u00e1cn\u00e1<\/li>\n\n\n\n<li><strong>Biomarkery<\/strong><br>sNfL (lehk\u00fd \u0159et\u011bzec neurofilament v s\u00e9ru) jako marker aktivity onemocn\u011bn\u00ed; sGFAP (gli\u00e1ln\u00ed fibril\u00e1rn\u00ed kysel\u00fd protein) jako marker astrocyt\u00e1rn\u00edho posti\u017een\u00ed.<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Therapeutische_Strategien\"><\/span>Terapeutick\u00e9 strategie<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Akuttherapie_Schubbehandlung\"><\/span>Akutn\u00ed l\u00e9\u010dba (l\u00e9\u010dba relapsu)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Standardn\u00ed l\u00e9\u010dba relapsu MOGAD:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vysoce d\u00e1vkovan\u00fd <em>Methylprednisolon<\/em> (HDMP)<\/strong><br>1000 mg i.v. denn\u011b po dobu 5 dn\u016f - prvn\u00ed linie<\/li>\n\n\n\n<li><em><strong>Plazmafer\u00e9za \/ imunoadsorpce<\/strong><\/em><br>V p\u0159\u00edpad\u011b nedostate\u010dn\u00e9 odpov\u011bdi HDMP; odstra\u0148uje MOG-IgG z plazmy; 5-7 cykl\u016f (retrospektivn\u00ed \u00fadaje ukazuj\u00ed \u00fa\u010dinnost v p\u0159ibli\u017en\u011b 50-70% p\u0159\u00edpad\u016f).<\/li>\n\n\n\n<li><strong><em>Intraven\u00f3zn\u00ed imunoglobuliny<\/em> (IVIG)<\/strong><br>2 g\/kg po dobu 5 dn\u016f; p\u0159i absenci odpov\u011bdi na HDMP a jako mo\u017enost po plazmafer\u00e9ze; pravd\u011bpodobn\u011b \u00fa\u010dinn\u00fd prost\u0159ednictv\u00edm saturace FcRn a konkurence Fc\u03b3R.<\/li>\n\n\n\n<li><strong>Vysazen\u00ed kortikosteroid\u016f<\/strong><br>Zvl\u00e1\u0161t\u011b d\u016fle\u017eit\u00e9 u MOGAD (\u010dast\u00e1 z\u00e1vislost na steroidech) - rychl\u00e9 sn\u00ed\u017een\u00ed m\u016f\u017ee vyvolat rebound epizody.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prophylaktische_Langzeittherapie\"><\/span>Profylaktick\u00e1 dlouhodob\u00e1 l\u00e9\u010dba<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">(off-label, \u017e\u00e1dn\u00fd registrovan\u00fd p\u0159\u00edpravek - stav 2026)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Indikace k dlouhodob\u00e9 l\u00e9\u010db\u011b je individu\u00e1ln\u00ed - ne v\u0161ichni pacienti ji pot\u0159ebuj\u00ed. Faktory: \u010detnost relaps\u016f, z\u00e1va\u017enost relaps\u016f, p\u0159etrv\u00e1vaj\u00edc\u00ed titry MOG-IgG, fenotypov\u00e9 rizikov\u00e9 faktory.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>L\u00e1tka<\/strong><\/td><td><strong>Mechanismus \u00fa\u010dinku<\/strong><\/td><td><strong>Situace s daty<\/strong><\/td><td><strong>\u00darove\u0148 d\u016fkaz\u016f<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Azathioprin<\/td><td>Blok\u00e1da synt\u00e9zy purin\u016f (z\u00e1visl\u00e1 na TPMT); inhibuje proliferaci T a B bun\u011bk.<\/td><td>Retrospektivn\u00ed studie; prob\u00edh\u00e1 n\u00e1rodn\u00ed RCT (Francie, studie TOMATO)<\/td><td>IIb-III (off-label)<\/td><\/tr><tr><td>Mykofenol\u00e1t mofetil (MMF)<\/td><td>Inhibitor inosinmonofosf\u00e1tdehydrogen\u00e1zy; inhibuje proliferaci lymfocyt\u016f<\/td><td>S\u00e9rie p\u0159\u00edpad\u016f; pravd\u011bpodobn\u011b \u00fa\u010dinn\u00e1, ni\u017e\u0161\u00ed prevence relapsu ne\u017e rituximab<\/td><td>III (off-label)<\/td><\/tr><tr><td>Rituximab<\/td><td>Anti-CD20 \u2192 deplece B-bun\u011bk; inhibuje produkci MOG-IgG<\/td><td>Nejv\u011bt\u0161\u00ed retrospektivn\u00ed soubor; \u00fa\u010dinn\u00fd, ale ne pro ka\u017ed\u00e9ho; zv\u00fd\u0161en\u00e9 riziko infekce<\/td><td>IIb (off-label)<\/td><\/tr><tr><td>Tocilizumab<\/td><td>Anti-IL-6R\u03b1 (iv); blokuje sign\u00e1ln\u00ed dr\u00e1hu IL-6 (JAK\/STAT3); inhibuje Th17\/plazmatick\u00e9 bu\u0148ky<\/td><td>Pozitivn\u00ed retrospektivn\u00ed \u00fadaje; v\u00fdsledky RCT pro NMOSD pozitivn\u00ed (TANGO)<\/td><td>IIb (off-label)<\/td><\/tr><tr><td>IVIG (iv\/subkut\u00e1nn\u00ed)<\/td><td>Saturace Fc receptoru; neutralizace MOG-IgG; saturace FcRn<\/td><td>Retrospektivn\u00ed \u00fadaje pozitivn\u00ed; mo\u017enost pro plodnost, t\u011bhotenstv\u00ed, infekce<\/td><td>IIb (off-label)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Klinische_Studien_%E2%80%93_2024%E2%80%932026\"><\/span>Klinick\u00e9 studie - 2024-2026<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Poprv\u00e9 prob\u00edh\u00e1 n\u011bkolik randomizovan\u00fdch, placebem kontrolovan\u00fdch studi\u00ed f\u00e1ze 3 pro MOGAD, kter\u00e9 by m\u011bly poskytnout d\u016fkazy t\u0159\u00eddy I:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Studie<\/strong><\/td><td><strong>L\u00e1tka<\/strong><\/td><td><strong>Mechanismus<\/strong><\/td><td><strong>C\u00edlov\u00e1 skupina<\/strong><\/td><td><strong>Stav<\/strong><\/td><\/tr><\/thead><tbody><tr><td>cosMOG<\/td><td>Rozanolixizumab (UCB7665)<\/td><td>Anti-FcRn IgG4-mAb: blokuje recyklaci IgG \u2192 urychluje degradaci IgG, sni\u017euje titr MOG IgG ~50 %<\/td><td>Dosp\u011bl\u00ed (\u2265 18 let), relaps, \u2265 1 relaps\/12 m\u011bs\u00edc\u016f<\/td><td>F\u00e1ze 3, mezin\u00e1rodn\u00ed; v\u016fbec prvn\u00ed studie f\u00e1ze 3 MOGAD<\/td><\/tr><tr><td>METEOROID<\/td><td>Satralizumab (anti-IL-6R sc.)<\/td><td>Anti-IL-6R (subkut\u00e1nn\u00ed); inhibuje JAK\/STAT3 \u2192 diferenciace Th17, zr\u00e1n\u00ed B-bun\u011bk, produkce IgG<\/td><td>Dosp\u011bl\u00ed + dosp\u00edvaj\u00edc\u00ed (\u2265 12 let); relaps, kter\u00e9mu p\u0159edch\u00e1zel \u2265 1 relaps<\/td><td>F\u00e1ze 3, mezin\u00e1rodn\u00ed, prob\u00edh\u00e1<\/td><\/tr><tr><td>TOMATO<\/td><td>Azathioprin<\/td><td>Inhibice synt\u00e9zy purin\u016f; \u0161iroce imunosupresivn\u00ed \u00fa\u010dinek<\/td><td>Francouzsk\u00e1 multicentrick\u00e1 studie; dosp\u011bl\u00ed s MOGAD<\/td><td>N\u00e1rodn\u00ed RCT, f\u00e1ze 3<\/td><\/tr><tr><td>MOGwAI<\/td><td>Nen\u00ed specifikov\u00e1no (pozorov\u00e1n\u00ed)<\/td><td>Biomarkerov\u00e1 studie: validace titru MOG-IgG, sNfL, sGFAP, sCD83 jako marker\u016f progrese<\/td><td>Mezin\u00e1rodn\u00ed kohortov\u00e1 studie<\/td><td>Pr\u016fb\u011b\u017en\u011b<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Neue_und_zukunftige_Therapiekonzepte\"><\/span>Nov\u00e9 a budouc\u00ed koncepty terapie<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Na z\u00e1klad\u011b molekul\u00e1rn\u00edch poznatk\u016f z posledn\u00edch let jsou diskutov\u00e1ny n\u00e1sleduj\u00edc\u00ed p\u0159\u00edstupy k MOGAD:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"BTK-Inhibitoren_Bruton-Tyrosin-Kinase\"><\/span>Inhibitory BTK (Brutonova tyrozinkin\u00e1za)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">BTK je \u00fast\u0159edn\u00ed kin\u00e1zou v signaliza\u010dn\u00ed kask\u00e1d\u011b B-bun\u011b\u010dn\u00e9ho receptoru (PI3K\/AKT\/MAPK). <strong><em>Tolebrutinib<\/em><\/strong> a dal\u0161\u00ed inhibitory BTK jsou ve v\u00fdzkumu RS a NMOSD; klinick\u00e9 studie MOGAD jsou v jedn\u00e1n\u00ed. Peror\u00e1ln\u00ed aplikace by byla v\u00fdhodou. Inhibice aktivace B-bun\u011bk i myeloidn\u00edch bun\u011bk (mikroglie-BTK).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Toleranzinduktion_MOG-Tolerisierung\"><\/span>Navozen\u00ed tolerance (tolerance MOG)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Slibn\u00fdm konceptem je indukce antigenn\u011b specifick\u00e9 tolerance (nap\u0159. pomoc\u00ed peptid\u016f MOG nebo p\u0159\u00edstup\u016f zalo\u017een\u00fdch na nano\u010d\u00e1stic\u00edch). Na str\u00e1nk\u00e1ch <strong><em>Charitativn\u00ed nadace Guthy-Jackson<\/em><\/strong> podporuje v\u00fdzkum l\u00e9\u010debn\u00fdch postup\u016f. V\u00fdhoda: \u017d\u00e1dn\u00e1 glob\u00e1ln\u00ed imunosuprese, <strong>Selektivn\u00ed eliminace autoreaktivity MOG<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Komplementinhibitoren\"><\/span>Inhibitory komplementu<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Vzhledem k tomu, \u017ee aktivace komplementu (C3a, C5a, MAC) je detekovateln\u00e1 v l\u00e9z\u00edch MOGAD, bylo by vhodn\u00e9 <strong><em>Eculizumab<\/em> (Anti-C5)<\/strong> nebo inhibitor C3 je teoreticky \u00fa\u010dinn\u00fd. Proto\u017ee se v\u0161ak komplex MAC (C5b-9) tvo\u0159\u00ed v mnohem men\u0161\u00ed m\u00ed\u0159e v MOGAD ne\u017e v NMOSD (kde <em>Eculizumab<\/em> je povolen), klinick\u00fd v\u00fdznam je nejist\u00fd.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Anti-Neonatal-Fc-Rezeptor-Strategien\"><\/span>Strategie proti neonat\u00e1ln\u00edmu Fc receptoru<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Krom\u011b <em>Rozanolixizumab<\/em> bude tak\u00e9 <strong><em>Efgartigimod<\/em><\/strong> (IgG-Fc fragment, kter\u00fd kompetitivn\u011b blokuje FcRn) pro dal\u0161\u00ed onemocn\u011bn\u00ed zprost\u0159edkovan\u00e1 IgG. Vzhledem k tomu, \u017ee patomechanismus blok\u00e1dy FcRn p\u0159\u00edmo sni\u017euje hladinu MOG-IgG, jedn\u00e1 se o obzvl\u00e1\u0161t\u011b c\u00edlen\u00fd p\u0159\u00edstup.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Autologe_hamatopoetische_Stammzelltransplantation_aHSCT\"><\/span>Autologn\u00ed transplantace krvetvorn\u00fdch bun\u011bk (aHSCT)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">U t\u011b\u017ek\u00fdch, refraktern\u00edch pr\u016fb\u011bh\u016f je aHSCT potenci\u00e1ln\u011b l\u00e9\u010debn\u00fdm konceptem: hlubok\u00e1 imunoablace a rekonstituce imunitn\u00edho syst\u00e9mu by mohla eliminovat autoreaktivn\u00ed klony T a B bun\u011bk. Pro MOGAD jsou k dispozici jen velmi omezen\u00e9 \u00fadaje; pou\u017eit\u00ed pouze ve specializovan\u00fdch centrech.<\/p>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Biomarker_und_Verlaufsmonitoring\"><\/span>Biomarkery a n\u00e1sledn\u00e9 sledov\u00e1n\u00ed<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">C\u00edlem sou\u010dasn\u00e9ho v\u00fdzkumu je rozhodov\u00e1n\u00ed o l\u00e9\u010db\u011b na z\u00e1klad\u011b biomarker\u016f:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Titr MOG-IgG (s\u00e9rum)<\/strong><br>Perzistence koreluje s rizikem relapsu; p\u0159i monof\u00e1zick\u00e9m pr\u016fb\u011bhu \u010dasto spont\u00e1nn\u00ed pokles titru; spolurozhoduje rozhodnut\u00ed o terapii.<\/li>\n\n\n\n<li><strong>S\u00e9rov\u00e9 neurofilamentov\u00e9 sv\u011btlo (sNfL)<\/strong><br>Marker axon\u00e1ln\u00edho po\u0161kozen\u00ed; zv\u00fd\u0161en\u00fd p\u0159i relapsu; normalizace jako marker odpov\u011bdi na l\u00e9\u010dbu<\/li>\n\n\n\n<li><strong>GFAP v s\u00e9ru (sGFAP)<\/strong><br>Astrocyt\u00e1rn\u00ed aktivace; ni\u017e\u0161\u00ed u MOGAD ne\u017e u NMOSD; m\u016f\u017ee poskytnout dopl\u0148uj\u00edc\u00ed informace.<\/li>\n\n\n\n<li><strong>sCD83<\/strong><br>Nov\u00fd kandid\u00e1tsk\u00fd biomarker (ve f\u00e1zi validace); pravd\u011bpodobn\u011b marker aktivace dendritick\u00fdch bun\u011bk a imunitn\u00ed aktivity.<\/li>\n\n\n\n<li><strong>Po\u010det bun\u011bk a b\u00edlkovin v mozkom\u00ed\u0161n\u00edm moku<\/strong><br>Pleocyt\u00f3za b\u011bhem epizod tahu; normalizace po l\u00e9\u010db\u011b<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Prognose_und_Besonderheiten\"><\/span>P\u0159edpov\u011b\u010f a speci\u00e1ln\u00ed funkce<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">V porovn\u00e1n\u00ed s AQP4+ NMOSD vykazuje MOGAD tendenci vykazovat <strong>P\u0159\u00edzniv\u011bj\u0161\u00ed p\u0159edpov\u011b\u010f<\/strong>, zejm\u00e9na lep\u0161\u00ed zotaven\u00ed zraku po zapnut\u00ed. D\u016fle\u017eit\u00e9 jsou v\u0161ak n\u00e1sleduj\u00edc\u00ed aspekty:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Monof\u00e1zick\u00e1 progrese<\/strong><br>P\u0159ibli\u017en\u011b 50% pacient\u016f; \u010dasto spont\u00e1nn\u00ed pokles titru; nemus\u00ed b\u00fdt nutn\u00e1 dlouhodob\u00e1 l\u00e9\u010dba.<\/li>\n\n\n\n<li><strong>Postup ve tvaru tahu<\/strong><br>P\u0159ibli\u017en\u011b 50%; vy\u0161\u0161\u00ed titr p\u0159etrv\u00e1v\u00e1; kumulativn\u00ed n\u00e1r\u016fst posti\u017een\u00ed mo\u017en\u00fd, ale pomalej\u0161\u00ed ne\u017e u NMOSD.<\/li>\n\n\n\n<li><strong>\u017d\u00e1dn\u00fd progresivn\u00ed kurz<\/strong><br>Na rozd\u00edl od RS nebyla pops\u00e1na postupn\u00e1 progrese bez relaps\u016f.<\/li>\n\n\n\n<li><strong>Citlivost na steroidy a z\u00e1vislost na nich<\/strong><br>Mnoho pacient\u016f v\u0161ak na kortikosteroidy reaguje velmi dob\u0159e: rychl\u00e9 vysazen\u00ed \u010dasto vyvol\u00e1v\u00e1 relapsy.<\/li>\n\n\n\n<li><strong>Speci\u00e1ln\u00ed pediatrick\u00e1 funkce<\/strong><br>ADEM nej\u010dast\u011bj\u0161\u00ed po\u010d\u00e1te\u010dn\u00ed projev u d\u011bt\u00ed (&lt;10 let); progn\u00f3za je \u010dasto dobr\u00e1, ale je t\u0159eba upozornit na riziko recidivy.<\/li>\n\n\n\n<li><strong>T\u011bhotenstv\u00ed: situace s nedostate\u010dn\u00fdmi \u00fadaji<\/strong><br>Obecn\u011b se riziko relapsu b\u011bhem t\u011bhotenstv\u00ed nezvy\u0161uje, ale po porodu by mohlo b\u00fdt rizikov\u00fdm faktorem (obdobn\u011b jako u RS).<\/li>\n<\/ul>\n\n\n\n<h1 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zusammenfassung_und_Ausblick\"><\/span>Shrnut\u00ed a v\u00fdhled<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\">MOGAD je nez\u00e1visl\u00e9, protil\u00e1tkami zprost\u0159edkovan\u00e9 autoimunitn\u00ed onemocn\u011bn\u00ed CNS, kter\u00e9 se vyzna\u010duje n\u00e1sleduj\u00edc\u00edmi hlavn\u00edmi rysy:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>C\u00edlov\u00fdm antigenem je protein MOG na vn\u011bj\u0161\u00ed stran\u011b oligodendrocyt\u016f a myelinov\u00fdch pochev.<\/li>\n\n\n\n<li>Patogenn\u00ed autoprotil\u00e1tky MOG-IgG1 po\u0161kozuj\u00ed myelin dv\u011bma paraleln\u00edmi efektorov\u00fdmi cestami: aktivac\u00ed komplementu (CDC, cca 50%) a vazbou Fc\u03b3R (ADCC\/ADCP, cca 50%).<\/li>\n\n\n\n<li>Krom\u011b toho protil\u00e1tky posiluj\u00ed aktivaci T-bun\u011bk prost\u0159ednictv\u00edm mechanism\u016f Fc\u03b3R.<\/li>\n\n\n\n<li>Sign\u00e1ln\u00ed dr\u00e1ha IL-6\/JAK\/STAT3 podporuje diferenciaci Th17 a zr\u00e1n\u00ed plazmatick\u00fdch bun\u011bk a je kl\u00ed\u010dov\u00fdm terapeutick\u00fdm c\u00edlem.<\/li>\n\n\n\n<li>V sou\u010dasn\u00e9 dob\u011b neexistuje \u017e\u00e1dn\u00e1 schv\u00e1len\u00e1 l\u00e9\u010dba (k \u00fanoru 2026); prob\u00edhaj\u00ed prvn\u00ed RCT f\u00e1ze 3 (cosMOG s rozanolixizumabem, METEOROID se satralizumabem).<\/li>\n\n\n\n<li>Terapie se posouv\u00e1 sm\u011brem ke strategi\u00edm zalo\u017een\u00fdm na biomarkerech a p\u0159izp\u016fsoben\u00fdm riziku.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Nejv\u00fdznamn\u011bj\u0161\u00edm pokrokem ve v\u00fdzkumu v posledn\u00edch letech je p\u0159esn\u00e9 rozlu\u0161t\u011bn\u00ed efektorov\u00fdch mechanism\u016f (komplement vs. FcR dr\u00e1ha) v\u00fdzkumn\u00fdmi skupinami, jako je nap\u0159. <strong>Meinl, Mader, Kawakami (LMU Mnichov)<\/strong>, co\u017e m\u00e1 p\u0159\u00edm\u00fd dopad na v\u00fdvoj terapie: Optim\u00e1ln\u00ed terapeutick\u00fd p\u0159\u00edstup se mus\u00ed zam\u011b\u0159it na produkci IgG (anti-CD20, inhibitory FcRn), stejn\u011b jako na efektorov\u00e9 mechanismy (komplement, Fc\u03b3R) a osu Th17\/IL-6.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Strategie indukce tolerance a inhibitory BTK p\u0159edstavuj\u00ed budouc\u00ed, mechanisticky zalo\u017een\u00e9 terapeutick\u00e9 principy, kter\u00e9 budou pravd\u011bpodobn\u011b v nadch\u00e1zej\u00edc\u00edch letech klinicky zkou\u0161eny.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Atherischer_Ole_%E2%80%93_Wirkstoffe_nach_Signalwegen_geordnet\"><\/span>Esenci\u00e1ln\u00ed oleje - \u00fa\u010dinn\u00e9 l\u00e1tky se\u0159azen\u00e9 podle sign\u00e1ln\u00edch drah<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">\u00da\u010dinn\u00e9 l\u00e1tky lze rozd\u011blit do skupin podle m\u00edsta jejich p\u016fsoben\u00ed v patofyziologii MOGAD. To je z\u00e1sadn\u00ed, proto\u017ee MOGAD m\u00e1 t\u0159i hlavn\u00ed osy: <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17\/IL-6<\/strong><\/li>\n\n\n\n<li><strong>Komplementov\u00fd syst\u00e9m\/oligodendrocyt\u00e1rn\u00ed ochrana<\/strong><\/li>\n\n\n\n<li><strong>Remyelinizace \/ diferenciace OPC<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Weihrauch_Boswellia_serrata_%E2%80%93_AKBA_und_Incensolacetat\"><\/span>Kadidlo (Boswellia serrata) - AKBA a incensol acet\u00e1t<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Podle spole\u010dnosti BCP se jedn\u00e1 o v\u011bdecky nejpodlo\u017een\u011bj\u0161\u00ed kandid\u00e1ta na MOGAD, kter\u00fd je v\u00fdjime\u010dn\u00fd sv\u00fdm rozsahem \u00fa\u010dink\u016f.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>AKBA (3-O-acetyl-11-keto-\u03b2-boswellov\u00e1 kyselina)<\/strong> je hlavn\u00ed \u00fa\u010dinnou l\u00e1tkou. AKBA m\u00e1 mnohostrann\u00e9 fyziologick\u00e9 \u00fa\u010dinky, v\u010detn\u011b protiinfek\u010dn\u00edch, protin\u00e1dorov\u00fdch a antioxida\u010dn\u00edch \u00fa\u010dink\u016f, a tak\u00e9 prok\u00e1zan\u00e9 neuroprotektivn\u00ed \u00fa\u010dinky. Podporuje obnovu a regeneraci nerv\u016f, chr\u00e1n\u00ed p\u0159ed ischemick\u00fdm po\u0161kozen\u00edm mozku, potla\u010duje neuroz\u00e1n\u011bt a zlep\u0161uje pam\u011b\u0165ov\u00e9 deficity. <a href=\"https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad\" target=\"_blank\" rel=\"noreferrer noopener\">Evropsk\u00e1 neurologick\u00e1 akademie<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>AKBA inhibuje STAT3<\/strong> v z\u00e1vislosti na d\u00e1vce, co\u017e je kl\u00ed\u010dov\u00fd mechanismus, proto\u017ee STAT3 je hlavn\u00edm efektorov\u00fdm transkrip\u010dn\u00edm faktorem sign\u00e1ln\u00ed dr\u00e1hy IL-6\/JAK, kter\u00e1 \u0159\u00edd\u00ed diferenciaci Th17 a zr\u00e1n\u00ed plazmatick\u00fdch bun\u011bk v MOGAD. Krom\u011b toho aktivace sign\u00e1ln\u00ed dr\u00e1hy Nrf2\/HO-1 pomoc\u00ed AKBA poskytuje sm\u011br pro sn\u00ed\u017een\u00ed oxida\u010dn\u00edho po\u0161kozen\u00ed, prevenci demyelinizace a podporu remyelinizace. <a href=\"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.nanolett.9b02220\" target=\"_blank\" rel=\"noreferrer noopener\">Publikace ACS<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AKBA p\u016fsob\u00ed jako molekul\u00e1rn\u00ed sp\u00edna\u010d, kter\u00fd blokuje tvorbu leukotrien\u016f prost\u0159ednictv\u00edm alosterick\u00e9 modulace 5-LOX a 15-LOX, ale z\u00e1rove\u0148 stimuluje produkci SPM (Specialised Pro-Resolving Mediators). T\u00edm aktivn\u011b posouv\u00e1 imunitn\u00ed odpov\u011b\u010f sm\u011brem k <strong>\u0158e\u0161en\u00ed z\u00e1n\u011btu<\/strong>, nejen jejich tlumen\u00ed. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39133885\/\" target=\"_blank\" rel=\"noreferrer noopener\">PubMed<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Acet\u00e1t incenzolu<\/strong> (t\u011bkav\u00e1 slo\u017eka kadidlov\u00e9ho esenci\u00e1ln\u00edho oleje, b\u00fdv\u00e1 BHS) aktivuje kan\u00e1ly TRPV3 v neuronech a tak\u00e9 PPAR-\u03b3 - Slo\u017eky kadidla mohou v\u00fdznamn\u011b sn\u00ed\u017eit IL-6, TNF-\u03b1 a GFAP (marker aktivace astrocyt\u016f) v mozku po vyvolan\u00e9m z\u00e1n\u011btu. <a href=\"https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200293\" target=\"_blank\" rel=\"noreferrer noopener\">Neurologie<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>D\u016fle\u017eit\u00e1 pozn\u00e1mka ke kvalit\u011b:<\/strong> Mezi jednotliv\u00fdmi v\u00fdrobky z boswellie jsou zna\u010dn\u00e9 rozd\u00edly v kvalit\u011b, n\u011bkter\u00e9 v\u00fdrobky (nap\u0159. H15 Ayurmedica\u00ae) obsahovaly v anal\u00fdz\u00e1ch pouze stopov\u00e9 mno\u017estv\u00ed charakteristick\u00fdch boswellov\u00fdch kyselin (0,31 mg AKBA). Naproti tomu v\u00fdrobky jako BOSWELLIASAN\u00ae (7,51 mg) a Sallaki\u00ae Tablets (7,88 mg) vykazovaly zna\u010dn\u00e9 mno\u017estv\u00ed AKBA a odpov\u00eddaj\u00edc\u00ed siln\u00e9 farmakologick\u00e9 \u00fa\u010dinky. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34358086\/\" target=\"_blank\" rel=\"noreferrer noopener\">Anal\u00fdza obsahu kyseliny boswellov\u00e9 a souvisej\u00edc\u00edch farmakologick\u00fdch \u00fa\u010dink\u016f l\u00e9\u010div\u00fdch p\u0159\u00edpravk\u016f na b\u00e1zi kadidla, kter\u00e9 moduluj\u00ed z\u00e1n\u011bty<\/a> a <a href=\"https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2025.1530977\/full\" target=\"_blank\" rel=\"noreferrer noopener\">Frontiers<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Produkt doTERRA <strong><a href=\"https:\/\/media.doterra.com\/us\/en\/pips\/frankincense-boswellic-acid-complex.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Komplex kadidlovn\u00edku s kyselinou boswelovou<\/a><\/strong> obsahuje 37,5 mg AKBA*<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Therapeutisch_relevante_AKBA-Zieldosen\"><\/span>Terapeuticky relevantn\u00ed c\u00edlov\u00e9 d\u00e1vky AKBA<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Z klinick\u00e9ho a preklinick\u00e9ho v\u00fdzkumu vypl\u00fdv\u00e1 n\u00e1sleduj\u00edc\u00ed obr\u00e1zek:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>C\u00edl aplikace<\/th><th>Denn\u00ed d\u00e1vka AKBA<\/th><th>Zdroj:<\/th><\/tr><\/thead><tbody><tr><td>Protiz\u00e1n\u011btliv\u00e9 (obecn\u011b)<\/td><td>100-200 mg<\/td><td>Studie na \u010dlov\u011bku kloub\/st\u0159evo<\/td><\/tr><tr><td>Inhibice NF-\u03baB \/ STAT3 (neuroz\u00e1n\u011bt)<\/td><td>200-400 mg<\/td><td>Zv\u00ed\u0159ec\u00ed modely, bun\u011b\u010dn\u00e9 kultury<\/td><\/tr><tr><td>Optim\u00e1ln\u00ed \u00fa\u010dinek na CNS (bari\u00e9rov\u00fd pr\u016fchod)<\/td><td>200-300 mg<\/td><td>Experiment\u00e1ln\u00ed data<\/td><\/tr><tr><td>Horn\u00ed dob\u0159e tolerovan\u00e1 denn\u00ed d\u00e1vka<\/td><td>400-600 mg<\/td><td>Studie tolerance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Umrechnung_auf_375_mg_AKBA_jeKapsel\"><\/span>P\u0159evod na 37,5 mg AKBA na kapsli<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>C\u00edlov\u00e1 denn\u00ed d\u00e1vka AKBA<\/th><th>Jednotky\/den<\/th><th>Praktick\u00e9 sch\u00e9ma<\/th><\/tr><\/thead><tbody><tr><td>150 mg<\/td><td>4 jednotky<\/td><td>2\u00d7 r\u00e1no + 2\u00d7 ve\u010der<\/td><\/tr><tr><td>200 mg<\/td><td><strong>5-6 jednotek<\/strong><\/td><td>3\u00d7 r\u00e1no + 2-3\u00d7 ve\u010der<\/td><\/tr><tr><td>300 mg<\/td><td>8 jednotek<\/td><td>4\u00d7 r\u00e1no + 4\u00d7 ve\u010der<\/td><\/tr><tr><td>400 mg<\/td><td>10-11 jednotek<\/td><td>3 \u00d7 3-4 jednotky denn\u011b<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Doporu\u010den\u00fd vstup:<\/strong> <strong>4 jednotky denn\u011b (= 150 mg AKBA)<\/strong>, rozd\u011blen\u00fd na 2 d\u00e1rky.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Po 2 t\u00fddnech - pokud je dob\u0159e sn\u00e1\u0161en - zvy\u0161te d\u00e1vku na 6 jednotek (= 225 mg).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wichtige_Einnahmehinweise\"><\/span>D\u016fle\u017eit\u00e9 pokyny pro p\u0159\u00edjem<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tuk je kl\u00ed\u010dov\u00fd:<\/strong> AKBA je vysoce lipofiln\u00ed. <strong>Biologick\u00e1 dostupnost se zvy\u0161uje 2-3kr\u00e1t<\/strong>, pokud se u\u017e\u00edv\u00e1 s tu\u010dn\u00fdm j\u00eddlem. Ide\u00e1ln\u00ed je olivov\u00fd olej, avok\u00e1do nebo hlavn\u00ed j\u00eddlo. U\u017e\u00edv\u00e1n\u00ed na la\u010dn\u00fd \u017ealudek v\u00fdrazn\u011b sni\u017euje vst\u0159eb\u00e1v\u00e1n\u00ed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Na\u010dasov\u00e1n\u00ed:<\/strong> AKBA m\u00e1 polo\u010das rozpadu p\u0159ibli\u017en\u011b 6 hodin, a proto <strong>2-3 d\u00e1vky denn\u011b<\/strong> To m\u00e1 v\u011bt\u0161\u00ed smysl ne\u017e jednor\u00e1zov\u00e1 d\u00e1vka, aby byla zachov\u00e1na rovnom\u011brn\u00e1 \u00fa\u010dinnost.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kombinace s BCP:<\/strong> AKBA (osa STAT3\/NF-\u03baB) a BCP (osa CB2\/Th17) se zab\u00fdvaj\u00ed r\u016fzn\u00fdmi sign\u00e1ln\u00edmi cestami v MOGAD a p\u016fsob\u00ed synergicky. Nejsou zn\u00e1my \u017e\u00e1dn\u00e9 farmakologick\u00e9 interakce.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u017dalude\u010dn\u00ed tolerance:<\/strong> Boswellia je obecn\u011b velmi dob\u0159e sn\u00e1\u0161ena. P\u0159i vy\u0161\u0161\u00edch d\u00e1vk\u00e1ch se vz\u00e1cn\u011b vyskytuje m\u00edrn\u00e9 podr\u00e1\u017ed\u011bn\u00ed \u017ealudku. Proto ji v\u017edy u\u017e\u00edvejte s j\u00eddlem nebo v p\u0159\u00edpad\u011b pot\u0159eby d\u00e1vku do\u010dasn\u011b sni\u017ete.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schwarzer_Pfeffer_oral\"><\/span>\u010cern\u00fd pep\u0159 (peror\u00e1ln\u011b)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Hlavn\u00ed \u00fa\u010dinn\u00e1 l\u00e1tka \u03b2-karyofylen (BCP) v oleji z \u010dern\u00e9ho pep\u0159e (<em>Piper nigrum<\/em>) zp\u016fsobuje pokles z\u00e1n\u011btliv\u00fdch cytokin\u016f IL-6, TNF-\u03b1, IL-17, IFN-\u03b3 a transkrip\u010dn\u00edch faktor\u016f Th17 (ROR-\u03b3t) a Th1 (T-bet) a v\u00fdrazn\u00fd n\u00e1r\u016fst protiz\u00e1n\u011btliv\u00fdch cytokin\u016f TGF-\u03b21, IL-10, IL-4 a transkrip\u010dn\u00edch faktor\u016f Th2 (GATA3) a Treg (Foxp3). Tyto \u00fa\u010dinky jsou striktn\u011b spojeny s aktivac\u00ed receptoru CB2.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Receptory CB2 a remyelinizace jsou p\u0159\u00edmo mechanicky propojeny: agonismus CB2 podporuje zr\u00e1n\u00ed OPC - agonista CB2 nov\u00e9 generace (Yhhu4952) v\u00fdznamn\u011b zv\u00fd\u0161il expresi myelinov\u00e9ho bazick\u00e9ho proteinu (MBP) a pod\u00edl zral\u00fdch oligodendrocyt\u016f v corpus callosum.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">D\u00e1vkov\u00e1n\u00ed \u010dern\u00e9ho pep\u0159e: 20 ... 200 mg\/d - co\u017e odpov\u00edd\u00e1 20 tr.\/d - proto je nejlep\u0161\u00ed u\u017e\u00edvat 7 trp. ka\u017ed\u00fdch 8 hodin (nejl\u00e9pe 5 trp. ka\u017ed\u00fdch 6 hodin pro vy\u0161\u0161\u00ed plazmatick\u00e9 hladiny) v nosn\u00e9m oleji v kapsli. Jako lipofiln\u00ed spolu s j\u00eddlem\/n\u00e1pojem s vysok\u00fdm obsahem tuku.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Schwarzer_Pfeffer_Inhalation\"><\/span>\u010cern\u00fd pep\u0159 (inhalace)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">D\u00e1vkov\u00e1n\u00ed: Inhalujte 3 trp. ka\u017ed\u00e9 4 hodiny b\u011bhem dne (polo\u010das rozpadu je 2-4 hodiny) na Liqui-Pad vyh\u0159\u00edvan\u00e9ho difuz\u00e9ru po dobu 20 minut a po ka\u017ed\u00e9m hlubok\u00e9m n\u00e1dechu zadr\u017ete dech na 5-8 sekund, v noci nechte difuz\u00e9r b\u011b\u017eet v m\u00edstnosti, nevdechujte p\u0159\u00edmo.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u010cern\u00fd pep\u0159 m\u016f\u017ee m\u00edt povzbuzuj\u00edc\u00ed \u00fa\u010dinek a zhor\u0161ovat sp\u00e1nek. V takov\u00e9m p\u0159\u00edpad\u011b jej v noci nerozptylujte.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pokud dojde k podr\u00e1\u017ed\u011bn\u00ed d\u00fdchac\u00edch cest (suchost) nebo se objev\u00ed bolest hlavy: Sni\u017ete d\u00e1vku nebo prodlu\u017ete intervaly.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Copaiba-Ol_oral_%E2%80%93_NUR_doTERRA\"><\/span>Olej z kopaiby (peror\u00e1ln\u00ed) - POUZE doTERRA<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">52,6 % BCP - odpov\u00edd\u00e1 14,7 mg BCP\/kapku - proto\u017ee BCP je lipofiln\u00ed, v\u017edy u\u017e\u00edvejte s j\u00eddlem\/n\u00e1pojem s vysok\u00fdm obsahem tuku!<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Podle klinick\u00fdch studi\u00ed bezpe\u010dnosti z toho vypl\u00fdv\u00e1 n\u00e1sleduj\u00edc\u00ed doporu\u010den\u00ed d\u00e1vkov\u00e1n\u00ed v z\u00e1vislosti na t\u011blesn\u00e9 hmotnosti:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOGAD-spezifische_Dosierungstabelle_doTERRA_Copaiba_525_BCP\"><\/span>D\u00e1vkovac\u00ed tabulka specifick\u00e1 pro MOGAD (doTERRA Copaiba 52.5 % BCP)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>T\u011blesn\u00e1 hmotnost<\/th><th><strong>Ochrana p\u0159\u00edrody<\/strong> (0,4 mg\/kg)<\/th><th><strong>Aktivn\u00ed tah<\/strong> (1,0 mg\/kg)<\/th><th><strong>Intenzivn\u00ed terapie<\/strong> (1,5 mg\/kg)<\/th><\/tr><\/thead><tbody><tr><td><strong>50 kg<\/strong><\/td><td>20 mg = <strong>1-2 kapky<\/strong><\/td><td>50 mg = <strong>3-4 kapky<\/strong><\/td><td>75 mg = <strong>5 kapek<\/strong><\/td><\/tr><tr><td><strong>60 kg<\/strong><\/td><td>24 mg = <strong>2 kapky<\/strong><\/td><td>60 mg = <strong>4 kapky<\/strong><\/td><td>90 mg = <strong>6 kapek<\/strong><\/td><\/tr><tr><td><strong>70 kg<\/strong><\/td><td>28 mg = <strong>2 kapky<\/strong><\/td><td>70 mg = <strong>5 kapek<\/strong><\/td><td>105 mg = <strong>7 kapek<\/strong><\/td><\/tr><tr><td><strong>80 kg<\/strong><\/td><td>32 mg = <strong>2 kapky<\/strong><\/td><td>80 mg = <strong>5-6 kapek<\/strong><\/td><td>120 mg = <strong>8 kapek<\/strong><\/td><\/tr><tr><td><strong>90 kg<\/strong><\/td><td>36 mg = <strong>2-3 kapky<\/strong><\/td><td>90 mg = <strong>6 kapek<\/strong><\/td><td>135 mg = <strong>9 kapek<\/strong><\/td><\/tr><tr><td><strong>100 kg<\/strong><\/td><td>40 mg = <strong>3 kapky<\/strong><\/td><td>100 mg = <strong>7 kapek<\/strong><\/td><td>150 mg = <strong>10 kapek<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"MOGAD-Phasen-adaptierte_Dosierung\"><\/span>F\u00e1zov\u011b p\u0159izp\u016fsoben\u00e9 d\u00e1vkov\u00e1n\u00ed MOGAD<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_1_Akuter_Schub_erste_2%E2%80%934_Wochen\"><\/span><strong>F\u00e1ze 1: Akutn\u00ed vzplanut\u00ed (prvn\u00ed 2-4 t\u00fddny)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>C\u00edl:<\/strong> Agresivn\u00ed potla\u010den\u00ed Th17, sn\u00ed\u017een\u00ed IL-6<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>D\u00e1vkov\u00e1n\u00ed:<\/strong> 1,0-1,5 mg\/kg denn\u011b<\/li>\n\n\n\n<li><strong>Odd\u011blen\u00ed:<\/strong> 3\u00d7 denn\u011b (optim\u00e1ln\u00ed pro kontinu\u00e1ln\u00ed aktivaci receptor\u016f CB2)<\/li>\n\n\n\n<li><strong>P\u0159\u00edklad 70 kg:<\/strong> 5-7 kapek denn\u011b, rozd\u011bleno jako 2+2+3 kapky<\/li>\n\n\n\n<li><strong>Kombinace:<\/strong> S AKBA (200-300 mg\/den pro inhibici STAT3) + vysok\u00e9 d\u00e1vky kortizonu (standard)<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_2_Schubremission_Erhaltung_langfristig\"><\/span><strong>F\u00e1ze 2: remise relapsu \/ udr\u017eov\u00e1n\u00ed (dlouhodob\u00e9)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>C\u00edl:<\/strong> Prevence relapsu, konstantn\u00ed protiz\u00e1n\u011btliv\u00fd t\u00f3n<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>D\u00e1vkov\u00e1n\u00ed:<\/strong> 0,4-0,7 mg\/kg denn\u011b<\/li>\n\n\n\n<li><strong>Odd\u011blen\u00ed:<\/strong> 2\u00d7 denn\u011b<\/li>\n\n\n\n<li><strong>P\u0159\u00edklad 70 kg:<\/strong> 2-3 kapky denn\u011b v d\u00e1vce 1+2 nebo 2+2<\/li>\n\n\n\n<li><strong>Kombinace:<\/strong> S AKBA (150 mg\/den) voliteln\u011b<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Phase_3_Monophasischer_Verlauf_Titer_fallend\"><\/span><strong>F\u00e1ze 3: Monof\u00e1zick\u00fd pr\u016fb\u011bh (klesaj\u00edc\u00ed titr)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>C\u00edl:<\/strong> Neuroprotekce, remyelinizace<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>D\u00e1vkov\u00e1n\u00ed:<\/strong> 0,2-0,4 mg\/kg denn\u011b<\/li>\n\n\n\n<li><strong>Odd\u011blen\u00ed:<\/strong> 1-2\u00d7 denn\u011b<\/li>\n\n\n\n<li><strong>P\u0159\u00edklad 70 kg:<\/strong> 1-2 kapky denn\u011b<\/li>\n\n\n\n<li><strong>Vyv\u00e1\u017een\u00ed je mo\u017en\u00e9<\/strong> po 6-12 m\u011bs\u00edc\u00edch stabiln\u00ed s\u00e9ronegativity<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Quellen\"><\/span>Zdroje<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Toxikologie (700 mg\/kg NOAEL)<\/strong><br><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27358239\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/27358239\/<\/a><\/li>\n\n\n\n<li><strong>Model EAE (\u00fa\u010dinnost 2,5-5 mg\/kg)<\/strong><br><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10377147\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10377147\/<\/a><\/li>\n\n\n\n<li><strong>Studie na lidech (100 mg bezpe\u010dn\u011b)<\/strong><br><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9104399\/\" target=\"_blank\" rel=\"noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9104399\/<\/a><\/li>\n\n\n\n<li><strong>Klinick\u00e1 studie (\u00fa\u010dinnost 126 mg\/den)<\/strong><br><a href=\"https:\/\/accurateclinic.com\/accurate-education-terpenes-caryophyllene\/\" target=\"_blank\" rel=\"noopener\">https:\/\/accurateclinic.com\/accurate-education-terpenes-caryophyllene\/<\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Copaiba-Ol_Inhalation\"><\/span>Olej z kopaiby (inhalace)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Krom\u011b \u010dern\u00e9ho pep\u0159e s maxim\u00e1ln\u00edm obsahem 38% BCP je kopaibov\u00fd olej s obsahem a\u017e 87% BCP mnohem siln\u011bj\u0161\u00ed, a proto je nejlep\u0161\u00ed volbou pro inhalaci.<br>Difuz\u00e9ry obvykle pracuj\u00ed se studen\u00fdm ultrazvukov\u00fdm (US) rozpra\u0161ov\u00e1n\u00edm. BCP se v\u0161ak odpa\u0159uje a\u017e od teploty p\u0159ibli\u017en\u011b 130 \u00b0C a ho\u0159\u00ed p\u0159i teplot\u00e1ch nad 180 \u00b0C. Mus\u00ed se proto pou\u017e\u00edvat vyh\u0159\u00edvan\u00e9 difuzory s \u0159\u00edzenou teplotou (nap\u0159. <a href=\"https:\/\/storz-bickel.com\" target=\"_blank\" rel=\"noreferrer noopener\">Volcano Classic, Volcano Hybrid nebo Mighty+<\/a>) v cenov\u00e9 relaci cca 270 - 415 eur a teplota by m\u011bla b\u00fdt nastavena co nejp\u0159esn\u011bji (kontrola infra\u010derven\u00fdm teplom\u011brem) na 160 \u00b0C.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Doporu\u010den\u00e9 d\u00e1vkov\u00e1n\u00ed oleje Copaiba (doTERRA) s obsahem 69 % BCP - 1 kapka obsahuje 18,6 mg BCP.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BCP m\u00e1 polo\u010das rozpadu 2-4 hodiny. Aby bylo dosa\u017eeno co nejst\u00e1lej\u0161\u00ed hladiny \u00fa\u010dinn\u00e9 l\u00e1tky, m\u011bla by b\u00fdt inhalace prov\u00e1d\u011bna v\u00fd\u0161e popsan\u00fdm zp\u016fsobem se 4 kapkami (co\u017e odpov\u00edd\u00e1 p\u0159ibli\u017en\u011b 200 mg BCP) ka\u017ed\u00e9 4 hodiny. Difuz\u00e9r je mo\u017en\u00e9 nechat b\u011bhem noci spu\u0161t\u011bn\u00fd v bl\u00edzkosti postele.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Zieldosen_und_benotigte_Tropfenzahl\"><\/span>C\u00edlov\u00e9 d\u00e1vky a po\u017eadovan\u00fd po\u010det kapek<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>C\u00edlov\u00e1 d\u00e1vka BCP<\/th><th>Kapky oleje Copaiba<\/th><th>Olej celkem (mg)<\/th><\/tr><\/thead><tbody><tr><td>20 mg BCP (po\u010d\u00e1te\u010dn\u00ed d\u00e1vka)<\/td><td><strong>~1 kapka<\/strong><\/td><td>~29 mg<\/td><\/tr><tr><td>50 mg BCP<\/td><td><strong>~3 kapky<\/strong><\/td><td>~72 mg<\/td><\/tr><tr><td>100 mg BCP (terapeutick\u00fd)<\/td><td><strong>~5-6 kapek<\/strong><\/td><td>~145 mg<\/td><\/tr><tr><td>120 mg BCP (horn\u00ed denn\u00ed d\u00e1vka)<\/td><td><strong>~6-7 kapek<\/strong><\/td><td>~174 mg<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>C\u00edlen\u011b inhalovan\u00fd BCP<\/th><th>Mno\u017estv\u00ed oleje na kapaln\u00e9 podlo\u017ece<\/th><th>Kapky<\/th><\/tr><\/thead><tbody><tr><td>~20 mg BCP inhala\u010dn\u011b<\/td><td>~40 mg oleje (~78 mg\/0,69)<\/td><td><strong>2-3 kapky<\/strong><\/td><\/tr><tr><td>~50 mg BCP inhala\u010dn\u011b<\/td><td>~100 mg oleje<\/td><td><strong>4-5 kapek<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Synergistische_MOGAD-Strategie_Multi-Target\"><\/span>Synergick\u00e1 strategie MOGAD (v\u00edce c\u00edl\u016f)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Vzhledem k tomu, \u017ee MOGAD m\u00e1 t\u0159i patomechanismy, vznik\u00e1 tato kombinace zalo\u017een\u00e1 na d\u016fkazech:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>\u00da\u010dinn\u00e1 l\u00e1tka<\/th><th>D\u00e1vka<\/th><th>Cesta sign\u00e1lu<\/th><th>V\u00fdznam MOGAD<\/th><\/tr><\/thead><tbody><tr><td><strong>BCP (peror\u00e1ln\u00ed)<\/strong><\/td><td>0,4-1,5 mg\/kg<\/td><td>CB2 \u2192 Th17\u2193, IL-6\u2193, Nrf2\/HO-1\u2191<\/td><td>\u2605\u2605\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>AKBA (\u00fastn\u00ed)<\/strong><\/td><td>200-400 mg\/den<\/td><td>STAT3\u2193, NF-\u03baB\u2193, 5-LOX\u2193<\/td><td>\u2605\u2605\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>BCP (inhalace, 160 \u00b0C)<\/strong><\/td><td>2-3 kapky, 2\u00d7 denn\u011b<\/td><td>Limbick\u00fd, rychl\u00fd pr\u016fnik do CNS<\/td><td>\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>Kadidlov\u00fd olej (inhala\u010dn\u00ed)<\/strong><\/td><td>3-4 kapky, 2\u00d7 denn\u011b<\/td><td>Incensol acet\u00e1t \u2192 TRPV3, PPAR-\u03b3<\/td><td>\u2605\u2605\u2605<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Tato \u010dty\u0159pil\u00ed\u0159ov\u00e1 strategie \u0159e\u0161\u00ed:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Th17\/IL-6<\/strong> (BCP peror\u00e1ln\u00ed + AKBA)<\/li>\n\n\n\n<li><strong>STAT3<\/strong> (AKBA)<\/li>\n\n\n\n<li><strong>Ochrana oligodendrocyt\u016f<\/strong> (aktivace BCP Nrf2)<\/li>\n\n\n\n<li><strong>Limbick\u00e1 modulace<\/strong> (inhalace)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wichtige_MOGAD-spezifische_Hinweise\"><\/span>D\u016fle\u017eit\u00e9 informace specifick\u00e9 pro MOGAD<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>\u017d\u00e1dn\u00e1 monoterapie<\/strong> - BCP\/AKBA jsou <strong>Dopl\u0148ky ke konven\u010dn\u00ed terapii<\/strong><br>(kortizon akutn\u011b, v p\u0159\u00edpad\u011b pot\u0159eby rituximab\/MMF\/IVIG profylakticky) - nikdy jako n\u00e1hrada<\/li>\n\n\n\n<li><strong>Sledov\u00e1n\u00ed biomarker\u016f:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Titr MOG-IgG ka\u017ed\u00fdch 3-6 m\u011bs\u00edc\u016f<\/li>\n\n\n\n<li>sNfL (Neurofilament Light) jako marker aktivity<\/li>\n\n\n\n<li>Pokud titry trvale klesaj\u00ed, zva\u017ete sn\u00ed\u017een\u00ed d\u00e1vky.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Sledujte spou\u0161t\u011b\u010d tahu<\/strong> - Hlavn\u00edm spou\u0161t\u011b\u010dem jsou infekce<br>V p\u0159\u00edpad\u011b infekce d\u00e1vkujte v p\u0159\u00edpad\u011b pot\u0159eby <strong>do\u010dasn\u011b zv\u00fd\u0161it na 1,5 mg\/kg<\/strong> (preventivn\u00ed)<\/li>\n\n\n\n<li><strong>Jatern\u00ed hodnoty pro Copaiba<\/strong> - Pokud &gt;1 mg\/kg po dobu &gt;3 m\u011bs\u00edc\u016f<br>Kontrola ALT\/AST ka\u017ed\u00e9 3 m\u011bs\u00edce<\/li>\n\n\n\n<li><strong>Alternativa \u010dern\u00e9ho pep\u0159e<\/strong> - Pro obavy z kopaiby: olej z \u010dern\u00e9ho pep\u0159e (25-38 % BCP)<br>Pak vypo\u010d\u00edtejte po\u010det kapek \u00d7 2<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"%CE%B1-Asaron_Kalmus-Ol_Acorus_calamus_%E2%80%93_direkt_oligodendrozytenprotektiv\"><\/span>\u03b1-Asaron (kalam\u00ednov\u00fd olej, <em>Acorus calamus<\/em>) - p\u0159\u00edmo oligodendrocyty chr\u00e1n\u00edc\u00ed<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Jedna z m\u00e1la \u00fa\u010dinn\u00fdch l\u00e1tek s <strong>p\u0159\u00edm\u00fd remyeliniza\u010dn\u00ed \u00fa\u010dinek<\/strong> je <em><strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37146420\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u03b1-Asaron<\/a><\/strong><\/em>. Zlep\u0161uje dysmyelinizaci zp\u016fsobenou ztr\u00e1tou zral\u00fdch oligodendrocyt\u016f po hypoxick\u00e9 ischemii prost\u0159ednictv\u00edm upregulace a aktivace PPAR-\u03b3 v astrocytech. To zvy\u0161uje expresi glutam\u00e1tov\u00e9ho transport\u00e9ru GLT-1 a odstra\u0148uje nadm\u011brn\u00fd glutam\u00e1t z extracelul\u00e1rn\u00edho prostoru, kter\u00fd by jinak zp\u016fsobil glutam\u00e1tem zprost\u0159edkovanou excitotoxicitu v OPC, inhiboval jejich diferenciaci a vyvolal bun\u011b\u010dnou smrt. <a href=\"https:\/\/www.klinikum.uni-heidelberg.de\/neurologische-klinik\/neurologie-und-poliklinik\/forschung\/neuroimmunology\/ag-molekulare-neuroimmunologie\/mog-enzephalomyelitis\" target=\"_blank\" rel=\"noreferrer noopener\">Univerzitn\u00ed nemocnice Heidelberg<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">PPARy v neurologii - <a href=\"https:\/\/www.frontiersin.org\/journals\/neuroscience\/articles\/10.3389\/fnins.2022.1060515\/pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Frontiers Editorial 2022<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pozor:<\/strong> V z\u00e1vislosti na sv\u00e9m p\u016fvodu obsahuje kalamitn\u00ed olej r\u016fzn\u00e1 mno\u017estv\u00ed \u03b2-asaronu, kter\u00fd je klasifikov\u00e1n jako mutagenn\u00ed. Pouze <strong>Vlastnosti bez \u03b2-asaronu<\/strong> (Acorus calamus var. americanus).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Podle sou\u010dasn\u00e9ho stavu (02.2026) nen\u00ed dostupnost na trhu uvedena.<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Geraniumol_Pelargonium_graveolens_%E2%80%93_Neuroinflammation_und_NO\"><\/span>Geraniov\u00fd olej (<em>Pelargonium graveolens<\/em>) - Neuroz\u00e1n\u011bt a NO<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7922935\/\" rel=\"nofollow noopener\" target=\"_blank\">Geraniov\u00fd olej<\/a> mohou b\u00fdt u\u017eite\u010dn\u00e9 u neurodegenerativn\u00edch onemocn\u011bn\u00ed, u nich\u017e je sou\u010d\u00e1st\u00ed patofyziologie neuroz\u00e1n\u011bt.<br>Hlavn\u00ed \u00fa\u010dinn\u00e1 l\u00e1tka <em>Citronellol<\/em> vykazovaly p\u0159i vy\u0161\u0161\u00edch koncentrac\u00edch vynikaj\u00edc\u00ed inhibi\u010dn\u00ed aktivitu na produkci NO, p\u0159i\u010dem\u017e rozhoduj\u00edc\u00ed jsou synergick\u00e9 interakce mezi jednotliv\u00fdmi slo\u017ekami.<br>Citronellol tak\u00e9 inhibuje NF-\u03baB - co\u017e je p\u0159\u00edmo relevantn\u00ed pro aktivaci mikrogli\u00ed v MOGAD.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Teebaum-Ol_Melaleuca_alternifolia_%E2%80%93_Mikroglia-Modulation\"><\/span>\u010cajovn\u00edkov\u00fd olej (<em>Melaleuca alternifolia<\/em>) - Modulace mikroglie<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10350368\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u010cajovn\u00edkov\u00fd olej<\/a> a jej\u00ed hlavn\u00ed slo\u017eky inhibuj\u00ed AChE a BChE a LOX. Optimalizace oxida\u010dn\u00edho stresu prost\u0159ednictv\u00edm antioxida\u010dn\u00edch vlastnost\u00ed, inhibice neuroz\u00e1n\u011btu a inhibice AChE\/BChE m\u016f\u017ee jako celkov\u00e1 strategie \u00fa\u010dinn\u011b p\u0159isp\u011bt k prevenci smrti neuron\u00e1ln\u00edch bun\u011bk.<br>Terpinen-4-ol (hlavn\u00ed \u00fa\u010dinn\u00e1 l\u00e1tka) tak\u00e9 specificky inhibuje polarizaci mikroglie M1.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Wirkstoffubersicht_nach_MOGAD-Signalwegen\"><\/span>P\u0159ehled \u00fa\u010dinn\u00fdch l\u00e1tek podle sign\u00e1ln\u00edch drah MOGAD<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>\u00da\u010dinn\u00e1 l\u00e1tka<\/th><th>Zdroj oleje<\/th><th>Sign\u00e1ln\u00ed dr\u00e1ha MOGAD<\/th><th>S\u00edla d\u016fkaz\u016f<\/th><\/tr><\/thead><tbody><tr><td><strong>\u03b2-karyofylen (BCP)<\/strong><\/td><td>\u010cern\u00fd pep\u0159, Copaiba<\/td><td>CB2 \u2192 Nrf2\/HO-1, PPAR-\u03b3; Th17\u2193, IL-6\u2193<\/td><td>\u2605\u2605\u2605\u2605 (model EAE)<\/td><\/tr><tr><td><strong>AKBA<\/strong><\/td><td>Kadidlo (<em>Boswellia serrata<\/em>)<\/td><td>STAT3\u2193, NF-\u03baB\u2193, 5-LOX\u2193, SPM\u2191, Nrf2\/HO-1\u2191.<\/td><td>\u2605\u2605\u2605\u2605 (studie CNS)<\/td><\/tr><tr><td><strong>Acet\u00e1t incenzolu<\/strong><\/td><td>Kadidlo (t\u011bkav\u00e1 \u010d\u00e1st)<\/td><td>TRPV3, PPAR-\u03b3, IL-6\u2193, GFAP\u2193<\/td><td>\u2605\u2605\u2605\u2605 (zv\u00ed\u0159ec\u00ed model)<\/td><\/tr><tr><td><strong>\u03b1-Asaron<\/strong><\/td><td>Calamus (<em>Acorus calamus<\/em>)<\/td><td>PPAR-\u03b3 \u2192 GLT-1\u2191 \u2192 ochrana OPC, p\u0159\u00edm\u00e1 remyelinizace<\/td><td>\u2605\u2605\u2605\u2605 (model hypoxie)<\/td><\/tr><tr><td><strong>Linalool<\/strong><\/td><td>levandule, medu\u0148ka<\/td><td>modulace NMDA, SERT, neuroprotekce<\/td><td>\u2605\u2605\u2605<\/td><\/tr><tr><td><strong>1,8-cineol<\/strong><\/td><td>Eukalyptus, rozmar\u00fdn<\/td><td>Inhibice AChE, antioxidant<\/td><td>\u2605\u2605\u2605\u2605 (prok\u00e1z\u00e1no v mozku)<\/td><\/tr><tr><td><strong>Citronellol<\/strong><\/td><td>Geranium<\/td><td>NO\u2193, NF-\u03baB\u2193, synergick\u00e9 \u00fa\u010dinky<\/td><td>\u2605\u2605<\/td><\/tr><tr><td><strong>Terpinen-4-ol<\/strong><\/td><td>\u010cajovn\u00edk<\/td><td>Mikroglie M1\u2193, LOX\u2193, AChE\u2193<\/td><td>\u2605\u2605<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Quellen_und_weiterfuhrende_Literatur\"><\/span><strong>Zdroje a dal\u0161\u00ed literatura<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Banwell B et al - Lancet Neurol. 2023;22:268-282<\/strong> Diagnostick\u00e1 krit\u00e9ria MOGAD<br><strong>PubMed (zdarma):<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36706773\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/36706773\/<\/a> <br><strong>ScienceDirect (abstrakt zdarma, pln\u00fd text za poplatek):<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1474442222004318\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1474442222004318<\/a> <br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8<\/a><\/li>\n\n\n\n<li><strong>Mader S et al - PNAS 2023<\/strong> <em>(Pozn\u00e1mka: v na\u0161em dokumentu je uvedeno jako \u201ePNAS 2024\" - spr\u00e1vn\u00fd rok vyd\u00e1n\u00ed je b\u0159ezen 2023)<\/em> Komplement vs. patomechanismus FcR, LMU Mnichov<br><strong>Pln\u00fd text PNAS (zdarma):<\/strong> <a href=\"https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2300648120\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.pnas.org\/doi\/10.1073\/pnas.2300648120<\/a> <br><strong>Tiskov\u00e1 zpr\u00e1va LMU (s vysv\u011btlen\u00edm):<\/strong> <a href=\"https:\/\/www.med.lmu.de\/bmc\/en\/news\/latest-news\/news-overview\/news\/autoimmune-disease-mogad-insights-into-pathomechanisms.html\" target=\"_blank\" rel=\"noopener\">https:\/\/www.med.lmu.de\/bmc\/en\/news\/latest-news\/news-overview\/news\/autoimmune-disease-mogad-insights-into-pathomechanisms.html<\/a> <br><strong>EAN koment\u00e1\u0159: Vydavatel\u00e9 se rozhodli, \u017ee se budou zab\u00fdvat ot\u00e1zkou, zda je mo\u017en\u00e9, aby se v p\u0159\u00edpad\u011b, \u017ee je to mo\u017en\u00e9, zab\u00fdvali i touto ot\u00e1zkou:<\/strong> <a href=\"https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.ean.org\/research\/resources\/neurology-updates\/detail\/complement-dependent-and-independent-pathomechanisms-of-myelin-oligodendrocyte-glycoprotein-mog-abs-implications-for-therapeutic-strategies-in-mog-antibody-associated-disease-mogad<\/a> <\/li>\n\n\n\n<li><strong>Kaneko K et al - Neurol Neuroimmunol Neuroinflamm. 2024;11(5):e200293<\/strong> Aktivace komplementu v CSF<br>\u010cl\u00e1nek e200293 je <strong>nelze nal\u00e9zt p\u0159\u00edmo<\/strong> - K dispozici je v\u0161ak souvisej\u00edc\u00ed p\u0159ehledov\u00fd \u010dl\u00e1nek MOGAD ze stejn\u00e9ho \u010d\u00edsla (e200275 od autor\u016f Moseley\/Zamvil):<br><strong>Neurologie NXI (e200275, stejn\u00e9 vyd\u00e1n\u00ed):<\/strong> <a href=\"https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200275\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200275<\/a> <br><strong>PubMed search for Kaneko 2024 MOGAD CSF:<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38996203\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/38996203\/<\/a> <em>(vede na e200275 - doporu\u010dujeme p\u0159\u00edm\u00e9 vyhled\u00e1v\u00e1n\u00ed v PubMedu pro e200293)<\/em><\/li>\n\n\n\n<li><strong>Cho EB et al - Front Immunol. 2024;15:1320094<\/strong> Dopl\u0148kov\u00fd vzor MOGAD vs. NMOSD<br><strong>Frontiers (pln\u00fd text zdarma):<\/strong> <a href=\"https:\/\/doi.org\/10.3389\/fimmu.2024.1320094\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.3389\/fimmu.2024.1320094<\/a> <em>(DOI p\u0159\u00edmo p\u0159\u00edstupn\u00fd)<\/em><\/li>\n\n\n\n<li><strong>Frontiers Immunol. 2025 - Modely EAE, patogeneze MOGAD<\/strong> <em>(Obecn\u011b se v dokumentu odkazuje na p\u0159ehledov\u00fd \u010dl\u00e1nek o sign\u00e1ln\u00edch drah\u00e1ch\/patomechanismech)<\/em><br><strong>Frontiers Immunol. 2025 (Sun et al., PMID 40406135):<\/strong> <a href=\"https:\/\/doi.org\/10.3389\/fimmu.2025.1535571\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.3389\/fimmu.2025.1535571<\/a><\/li>\n\n\n\n<li><strong>PMC 2023 - Komplexn\u00ed p\u0159ehled patofyziologie MOGAD<\/strong><br><strong>PMC Pln\u00fd text (zdarma):<\/strong> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9597055\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9597055\/<\/a><\/li>\n\n\n\n<li><strong>PMC 2024 - aktualizovan\u00fd p\u0159ehled Klinick\u00e9 spektrum, patogeneze, l\u00e9\u010dba<\/strong><br><strong>PubMed\/PMC (Trewin et al., Autoimmun Rev 2025):<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39577549\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/39577549\/<\/a><br><strong>Pln\u00fd text PMC:<\/strong> <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9294102\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9294102\/<\/a> <em>(Terapie monoklon\u00e1ln\u00edmi protil\u00e1tkami NMOSD\/MOGAD)<\/em><\/li>\n\n\n\n<li><strong>St\u00f6gbauer J et al - Autoimmunity Reviews 2025;103970<\/strong> Terapeutick\u00e9 p\u0159\u00edstupy Dosp\u011bl\u00ed MOGAD<br><strong>ScienceDirect (otev\u0159en\u00fd p\u0159\u00edstup, pln\u00fd text zdarma):<\/strong> <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1568997225002319\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1568997225002319<\/a> <br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1016\/j.autrev.2025.103970\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1016\/j.autrev.2025.103970<\/a> <br><strong>N\u011bmeck\u00e9 shrnut\u00ed:<\/strong> <a href=\"https:\/\/www.reine-nervensache.de\/therapieansaetze-bei-mogad-von-der-akutbehandlung-zur-langfristigen-strategie\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.reine-nervensache.de\/therapieansaetze-bei-mogad-von-der-akutbehandlung-zur-langfristigen-strategie\/<\/a> <\/li>\n\n\n\n<li><strong>Odborn\u00e9 stanovisko k nov\u011b vznikaj\u00edc\u00edm l\u00e9\u010div\u016fm v roce 2025 - prost\u0159ed\u00ed klinick\u00fdch studi\u00ed<\/strong><br><strong>Tandfonline (abstrakt zdarma, pln\u00fd text za poplatek):<\/strong> <a href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2025.2565189\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2025.2565189<\/a><br><strong>DOI:<\/strong> <a href=\"https:\/\/doi.org\/10.1080\/14728214.2025.2565189\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.1080\/14728214.2025.2565189<\/a><br><\/li>\n\n\n\n<li><strong>Studijn\u00ed skupina NEMOS<\/strong> <a href=\"https:\/\/www.nemos-net.de\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.nemos-net.de<\/a><br><\/li>\n\n\n\n<li><strong>P\u0159ehled studi\u00ed zam\u011b\u0159en\u00fdch na pacienty (cosMOG\/METEOROID):<\/strong><br>Projekt MOG - <a href=\"https:\/\/mogproject.org\/clinical-trials\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/mogproject.org\/clinical-trials\/<\/a><br>ClinicalTrials.gov - cosMOG - <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05063162\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/clinicaltrials.gov\/study\/NCT05063162<\/a><\/li>\n<\/ul>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\">Ve\u0161ker\u00fd obsah byl sv\u011bdomit\u011b prozkoum\u00e1n a odr\u00e1\u017e\u00ed sou\u010dasn\u00fd (02.2026) publikovan\u00fd stav znalost\u00ed. M\u00e1 pouze informativn\u00ed charakter a nenahrazuje odbornou l\u00e9ka\u0159skou konzultaci.<br>V\u0161echna doporu\u010den\u00ed ohledn\u011b d\u00e1vkov\u00e1n\u00ed mus\u00ed b\u00fdt dohodnuta s o\u0161et\u0159uj\u00edc\u00edm l\u00e9ka\u0159em. <br>Souvisej\u00edc\u00ed studie poskytuj\u00ed l\u00e9ka\u0159i dal\u0161\u00ed l\u00e9ka\u0159sk\u00e9 a v\u011bdeck\u00e9 informace.<\/p>\n<\/blockquote>","protected":false},"excerpt":{"rendered":"<p><span class=\"span-reading-time rt-reading-time\" style=\"display: block;\"><span class=\"rt-label rt-prefix\">Doba \u010dten\u00ed<\/span> <span class=\"rt-time\"> 17<\/span> <span class=\"rt-label rt-postfix\">minuty<\/span><\/span>Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Was ist MOGAD? Jeder kennt elektrische Leitungen: Sie sind mit einer Isolierung versehen, die die einzelne Leiter im Kableb\u00fcndel von einander trennt, damit die Signale in ihnen einander nicht st\u00f6ren und unverf\u00e4lscht von A nach B gelangen.Das R\u00fcckenmark beinhaltet einen ganzen Strang vieler solcher Kabelb\u00fcndel. Sie leiten die Nervensignale vom&hellip;&nbsp;<a href=\"https:\/\/csiag.eu\/cs\/blog\/2026\/02\/17\/mogad-mog-antikoerper-assoziierte-erkrankung\/\" rel=\"bookmark\">\u010c\u00edst d\u00e1le \"<span class=\"screen-reader-text\">MOGAD - onemocn\u011bn\u00ed spojen\u00e9 s protil\u00e1tkami MOG<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[1078,354],"tags":[94,5721,5717,5720,5714,5713,5711,5715,5719,5716,77,90,5712,5718],"class_list":["post-12718","post","type-post","status-publish","format-standard","hentry","category-medizin","category-medizin-gesundheit","tag-antikoerper","tag-bcp","tag-glykoprotein","tag-igg","tag-mog","tag-mogad","tag-molekulare-signalwege","tag-myelin","tag-myelinscheide","tag-oligodendrozyten","tag-pathophysiologie","tag-rezeptoren","tag-therapiekonzepte","tag-transmebranprotein"],"modified_by":"Achim Goerner","_links":{"self":[{"href":"https:\/\/csiag.eu\/cs\/wp-json\/wp\/v2\/posts\/12718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/csiag.eu\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csiag.eu\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csiag.eu\/cs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/csiag.eu\/cs\/wp-json\/wp\/v2\/comments?post=12718"}],"version-history":[{"count":0,"href":"https:\/\/csiag.eu\/cs\/wp-json\/wp\/v2\/posts\/12718\/revisions"}],"wp:attachment":[{"href":"https:\/\/csiag.eu\/cs\/wp-json\/wp\/v2\/media?parent=12718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csiag.eu\/cs\/wp-json\/wp\/v2\/categories?post=12718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csiag.eu\/cs\/wp-json\/wp\/v2\/tags?post=12718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}